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Among the most threatening diseases in the world, cancer and multi-drug resistant bacteria 
infections are two of the most serious. Mesoporous silica nanoparticles or nanostructures (MSNs) 
provide nanovesicles for transporting anti-cancer or anti-microbial drugs. The MSNs can easily be 
functionalized with gatekeepers to ensure that these drugs are released when and where they are 
needed. It is known that membrane disruption is more difficult for bacteria to gain resistance. For 
this reason, a small surfactant library was designed with potential of having significant activity 
toward both gram-positive and gram-negative bacteria. Once the surfactants were synthesized, 
they were characterized using NMR, IR, and mass spectroscopy.  Their activity was then tested 
against Micrococcus luteus and Methicillin Resistant-Staphylococcus aureus. The surfactants with 
best activity were then successfully incorporated into MSN structures. Benzalkonium chloride 
(BAC), a commercially available antiseptic, had the lowest minimum inhibitory concentration 
(MIC) of the surfactants tested, thus making it the best candidate for use in the proof of study for 
the designed delivery system. The MSN-based system for treatment of bacterial infections 
consisted of BAC loaded, amine functionalized MSNs anchored to a vancomycin gatekeeper via 
a protease cleavable peptide linker. The peptide was designed to have two cleavage positions by 
proteases for optimal cleaving. Vancomycin was chosen for its bulky size and activity toward 
bacteria. The system designed for treatment of cancer was focused on the non-specific nature of 
the therapeutic peptide SA-D-K6L9-AS. The peptide needed to be “gift-wrapped” and sent to the 
exact location of the tumor to minimize systemic toxicity. The proposed system for this was to use 
MSNs built directly around a self-assembling version of D-K6L9, then embedding iron oxide 
nanoparticles on the surface of the MSN, and finally enveloping the MSN in a lipid membrane. 
The drug would be released when the iron oxide particles were heated via radio-wave mediated 
hyperthermia. As proof of concept, MSNs built around a rhodamine-B labeled, self-assembling 
version of D-K6L9 were used and tested against GL26 (glioma), B16F10 (melanoma), and NSC 
(neural stem cells) cell lines, both with and without the gatekeeping system. The outcome was as 
anticipated, the gatekeeper kept the peptide inside and the cell viabilities remained high. The next 
steps of these projects will be to continue in-vitro testing before moving on to mouse model studies. 
The MSNs in both projects were characterized using DLS, Zeta potential, TGA, and TEM. Overall, 
the proposed MSN-based drug delivery systems appear to exhibit promising potential for new 
approaches towards treatment of both antibiotic resistance and cancer. 
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Chapter 1 - Introduction 
 Nanotechnology 
Nanotechnology is increasing in popularity for treatment of a wide range of diseases. This may 
be due to the versatility of nanoparticles (NPs). NPs already are in wide use in the industry 
extending from cosmetics to electrical transformer and so much more.1 Over the last several years, 
NP or nanotechnology-based treatments have been approved for clinical use in the medical field 
for cancer treatment, imaging, vaccinations, and more. Some better-known examples include 
Abraxane and Doxil.2 As of 2016, 51 “nanomedicines” had been approved by the Food and Drug 
Administration and nearly 80 more where in clinical trials.3 Agricultural uses currently in use or 
being investigated range from fertilizers to plant breeding.4 As interest increases the field of 
nanotechnology, more issues begin to emerge. One common issue in NP synthesis is the ability to 
produce NPs in bulk in a cost effective and time efficient manner. 
 Mesoporous silica nanoparticles 
Mesoporous silica nanoparticles (MSNs) are one type of NP that is relatively easy to synthesize 
and cost effective. As their name suggests they are comprised of a silica-oxygen scaffold that 
contains pores. The pores can be filled with cargo that either occupies the empty space or that 
interacts with the silica scaffold. Their synthesis generally consists of mixing a surfactant in water 
and allowing micelles to form in the presence of a catalyst. Then a templating agent, usually 
tetraethyl orthosilicate, is added and allowed to reactant for several hours producing a white 
precipitate that is easily isolated by filtration or centrifugation.5 The synthesis occurs though a 
simple sol-gel reaction, where the silicate is first hydrolyzed and then allowed to condense with 
another silicate or silanol molecule forming a network of silica-oxygen bonds around the 
templating agent.6 The size of the nanoparticles and their pore size can be manipulated by varying 
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the concentration of the starting reagents, by changing the length of the reaction, or by changing 
the temperature/pressure of the reaction. The resulting MSNs must be acid washed or calcinated 
to remove the surfactant prior to drug loading. These NPs are readily functionalized and 
biocompatible, making them an excellent option for drug delivery.7 Unfortunately, MSNs do have 
their drawbacks. One of these drawbacks is loading efficiency. A “high” MSN loading efficiency 
can be as low as 10%.8 This can be increased with a novel type of synthesis, which will be 
discussed chapter 3. The use of cetrimonium bromide (CTAB) as a templating agent also can pose 
a problem because it is toxic and difficult to completely remove from the MSN. Another issue is 
the non-specific release and release rate of MSNs. Luckily, this can be finetuned using gatekeepers. 
 Antibiotic Resistance 
Antibiotics are one of the most widely used medications globally. From 2010-2011 there 
were over 154 million antibiotics prescribed in the United States alone. Nearly half of the 
outpatient prescriptions were written for common illnesses that do not require antibiotic treatment. 
Of the total prescribed, it is estimated nearly 1 in 3 prescriptions were considered unnecessary.9 
This is also not accounting for the antibiotics provided to livestock in an attempt to ensure food 
safety and quality. In 2014 there were nineteen European countries where antibiotics were 
available over the counter.10 The misuse and overuse of antibiotics is rapidly creating a global 
threat. Bacteria are often thought to be simple, single celled organisms, but their means of evading 
antibiotics can be quite intricate. Due to their single cell nature, they can quickly adapt and become 
resistant. The typical path of resistance is as follows: antibiotics are administered, a small 
population of bacteria are resistant and survive the treatment, then these bacteria repopulate and 
form a resistant colony or strain.11 With proper use, this process can take a long time due to the 
host’s ability to fight the few remaining cells, but with the widespread use of antibiotics this 
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process is occurring much more quickly and “superbugs” are becoming commonplace names. The 
CDC estimates that over two million illnesses are causes by antibiotic resistance. Of these, 
approximately twenty-three thousand resulted in death.11 More shockingly, over half of the deaths 
are attributed to one infection: Clostridium difficile. Resistance is not a new concept, in fact 
resistance was reported three years prior to the introduction of the first approved antibiotic, 
penicillin, in 1943.11 One of the biggest issues being faced are multi-drug resistance.  
Bacterial means of resistance can be extremely diverse. Bacteria can develop efflux pumps 
to manually push the drug out of the cell. They are also capable of modifying their cell wall to be 
less permeable causing less drug to enter the cell.12 If the drug manages to enter the cell, some 
bacteria have been known to alter the target site rendering the antibiotic useless. Another form of 
resistance occurs when the cell develops an inactivating enzyme or manage to use other enzyme 
altogether.12 Taking a closer look, it becomes clear that traditional antibiotics have a mechanism 
of action that target a biological function within the cell thus leading to cell death. Bacteria, 
however, have often found ways to resist this time of treatment suggesting a new mechanism of 
action may be needed. 
 Surfactants 
Those familiar with surfactants likely associate them with industrial or home-cleaning 
usage. They have been known for their foaming and emulsification abilities, but have be used as 
wetting agents, anti-corrosion agents, and much more since their discovery.13 Benzalkonium 
chloride (BAC) is a unique example of a commonly used surfactant in hospitals and antiseptic 
wipes. With antibiotic resistance on the rise, research is beginning to focus on development of new 
treatment for these resistant infections. The antimicrobial activity of surfactants has become a 
leading question for new research. The mechanism of action of surfactants is still under 
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investigation, but is widely accepted as an association of the surfactant molecules with the cell 
membrane of the bacteria which leads to penetration and cytoplasmic leakage. This method of 
action would be more difficult to gain resistance towards in comparison to traditional antibacterial 
reagents.22 Recently, surfactants have also been studied for their application in nanotechnology as 
capping agents and templates for mesoporous structures.23 
Structurally, surfactants are relatively simple. They consist of a hydrophilic head group 
and a hydrophobic tail group. This makes them amphiphilic molecules. Their hydrophobic tail 
often consists of a hydrocarbon tail, while the hydrophilic head group can varies drastically 
depending on the desired function of the surfactant. Head groups can also carry charges which are 
balanced by a counter ion, breaking surfactants into five main groups: biosurfactants, cationic, 
anionic, zwitterionic, and non-ionic. Each group generally has its own set of primary uses, as well 
as advantages and disadvantages. Often surfactants are not easily biodegradable and are toxic to 
aquatic life.13 This is one of the main hurdles in the field of surfactants. Surfactants can also be 
“Gemini” meaning that they have two hydrophilic heads and/or hydrophobic tails. Gemini 
surfactants have been more powerful than their single headed counterpart. Some studies that have 
investigated surfactants with multiple heads have found an increase in antimicrobial activity as 
well.  Cationic surfactants have shown to have particularly high antimicrobial activity. They have 
been heavily investigated over the last several decades. Cationic surfactants can range from single 
headed to multi-headed molecules with varying chain lengths and types. The spacers between the 
heads has also been manipulated. Changes in the head, tail, and spacer have been proven to change 
their activity. The most common head group is quaternary ammonium. These amines are 
considered “war-heads” and often have great biological activity.13 Further manipulation and better 
characterization could give way to a new treatment of bacterial infections.  
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 Cancer 
It is well known that cancer is among the leading causes of death globally, however, the 
word cancer itself is misleading. It paints a picture of singularity, while the reality is that cancer is 
a large group of diseases that all share the common trait of uncontrolled cell division. The number 
of expected new cases of cancer in the United States alone is 1,762,450 for the year of 2019.14 The 
expected deaths from cancer in the U.S. for the same period is over six hundred thousand. Although 
the overall death rate in the U.S. has fallen over the last serval years, more than half of the global 
new cases of cancer have occurred in developing portions of the world where novel treatments are 
not as readily available. There are also several cancer risk factors that are on the rise in developed 
nations, such as obesity, which threaten to increase the number of new and potentially fatal cases 
of the cancer.14   
 Cancer treatment 
Cancer is an extremely complex set of diseases, making treatment difficult. The same 
treatment may have significantly different outcomes on two different types of cancer. Generally, 
the most common forms of treatment include chemotherapy, radiation therapy, and surgery, but 
recently immunotherapy and targeted therapies have been becoming more prevalent. There are 
also treatments such as hormone therapy and stem-cell therapy that are used to help mitigate the 
symptoms and progression on cancer, but do not cure cancer.15  
 Surgery 
Surgery is a type of treatment that is utilized when a solid, tumorous mass occurs in the 
body. The goal is to remove the entire tumor, but sometimes this is not possible. If the tumor has 
become too vascular or the surgery threatens to damage an organ, the tumor may only be reduced 
in size and then treated with another type of therapy.16 There are various methods for removing 
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cancerous tissue including, but not limited to, traditional surgical removal using scalpels, laser 
removal of tissue, cryosurgery, and hyperthermia. All these surgery techniques are performed with 
the use of anesthesia, whether it be local, regional, general.16 Minimally invasive surgery is 
preferred to open surgery because of the lowered risk of infection and the shorter recovery time, 
but the surgeon will perform open surgery if there are complications or laparoscopic techniques 
are not possible.16 Painful recovery, risk of infection, risks associated with general anesthesia, and 
high cost of surgery are common flaws associated with the treatment. 
 Radiation therapy 
Radiation therapy is another treatment technique commonly used for solid tumorous 
masses, but it can also be used for treatment of cancer-caused conditions. Radiotherapy utilizes 
high doses of radiation in an attempt to shirk tumors and cell cancerous cells. It is often used in 
combination with another type of cancer treatment.17 There are two types of radiation therapy, 
external beam radiation and internal radiation. The type that is used for treatment is dependent on 
many factors including type of cancer, size, and location of tumor. When used properly radiation 
therapy’s success can range from curing cancer, slowing its growth, or preventing return of 
cancerous cells.17 A major drawback for the technique is that radiation itself is known to cause 
cancer in some cases. The technique also generally comes with a laundry list of side effects ranging 
from hair loss to fertility issues depending on the location radiation is applied to.18 
 Chemotherapy 
Chemotherapy is a treatment that utilizes a cancer-killing drug that can be administered to 
the patient either orally on intravenously. Often, these drugs are non-specific and kill healthy cells 
in the process leading to undesirable side effects. Chemotherapy can be used as a sole source of 
treatment or before, during, or after one of the other therapy options depending on the type and 
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stage of cancer.19 This is process can be extremely taxing on the body and may not be possible for 
all patients depending on their health. For several years now, there has be much research done in 
an attempt to make drugs that are either more specific or that have reduced side effects.  
 Immunotherapy 
Immunotherapy is one of the newest forms of treatment for cancer. It is a technique that 
may not be available to all patients at this time. In immunotherapy, naturally occurring immune 
cells within the body to treat cancer. This process can be done in a few different ways. Checkpoint 
inhibitors are drugs given to a patient that increase the likelihood of the immune system 
recognizing cancerous cells.20 Adaptive cell transfer is a method that takes T-cells from the tumor 
and determines which are most likely to attack the cancerous cells. These cancer-sensitive T-cells 
are then cultured ex-vivo over the course of a few weeks to amplify the number of cells and then 
they are re-administered to the patient.20 Another type of immunotherapy utilizes monoclonal 
antibodies, or antibodies that have been synthesized to bind specially to certain receptor in the 
body. Monoclonal antibodies used for immunotherapy are engineered to bind to receptors of 
cancer cells and attach immune cells to the area.20 There are several other forms of immunotherapy 
being investigated, but currently there are only five classes of immunotherapy that have been 
approved for clinical use in the U.S.21 Immunotherapy appears to be promising field of treatment 
for cancer, but is not without side effects of its own. These side effects may include pain and 
swelling to heart palpitations and risk of infection.20 Immunotherapy results also can vary greatly 
from patient to patient.21 
 Summary 
Both cancer and bacteria are complex to treat. Bacterial readily can become resistant to 
many of the common approaches to treatment, making a drug with a different mechanism of action 
8 
desirable. Current cancer treatments are to thank for the decreased death rate from cancer in the 
U.S., but these treatments still have severe side effects and are not always 100% effective are 
killing cancer. Nanotechnology may hold the key to solving both problems. Employing the use of 
MSNs to carry various drugs could help limit side effects from drugs that are toxic to healthy cells. 
The use of surfactants as antimicrobials could open the door for higher loading efficiencies and 





Chapter 2 - Understanding Gatekeepers 
Gatekeepers are molecules that keep the cargo inside of the MSN pores. The gatekeeper 
may do this in a few ways. It may envelope MSN or coat it complete. It also may be attached to 
the surface of the MSN and sterically cover the pores. An advantage of using gatekeepers is that 
they can have specific modes of release which can greatly enhance the ability to actively target in-
vivo.7 While there are currently a vast number of gatekeepers being investigated, the majority can 
be divided into three main categories: pH dependent release, temperature or radiation release, and 
degradative release. 
 pH Dependent Release 
In the field of drug delivery release of a drug caused by specific stimuli is considered to an 
advantage because it can allow for targeted treatment. One stimulus commonly considered is pH. 
This is because of the acidic environment found in tumor, inflamed tissues, lysosomes, and 
endosomes. Change in pH can trigger release of the cargo via different methods. There are pH 
cleavable molecules, pH soluble molecules, molecules that have conformational changes due to 
pH change, charge interactions change due to pH, and molecules that can change between 
hydrophilic and hydrophobic due to pH.7 
 Soluble Release 
Quantum dots (QDs) are extremely small inorganic crystals measuring only a few nanometers 
in width.24 QDs can be made from several different types of materials, giving them varying 
stabilities and characteristics. Some QDs are soluble under varying pHs, making them excellent 
gatekeepers for MSNs. The QDs essentially plug the pores of the MSN until they are in an acidic 







Table 2.1: Various types of pH-dependent gatekeepers. a. soluble gatekeeper, dissolves in acidic 
environment. b. electrostatic type gatekeeper, change interaction weakened in lower pH. c. acid cleavable linked 













One study utilized Zinc-oxide (ZnO) QDs as gatekeepers. ZnO QDs are broadly studied due to 
their biocompatibility and low cost. They are particularly of interest as gatekeepers for MSNs used 
to treat cancer due the anti-cancer characteristics of zinc ions.25  
 Guest-host release 
Another common pH dependent gatekeeper method utilizes the concept of guest-host 
assemblies. Generally, the host molecule is a large cyclic molecule, while the guest is a much 
smaller molecule that can be held within the host.26 When this concept is applied as a gatekeeper 
for MSNs the guest molecule is anchored to the MSN via a covalent bond. Because the guest 
molecule is small it does not impede on the drug release from the pores. Once the host molecule 
is introduced, however, its large, bulky nature sterically covers the pores keeping the drug inside. 
Once the host vacates, the drug is then released (depicted in table 2.1).25 An example of theses host 
molecules is cyclodextrin (CD), a large cyclic molecule containing varying numbers of D-glucose 
units linked by 1,4-glucosidic residues.26 CDs residues are hydrophobic, so their guests must be 
hydrophobic as well.26 A study done by Zhang et al. in 2014 constructed an MSNs containing a 
variety of guest molecules capped with CDs for the potential treatment of bladder cancer. The host 
released the guest molecule in low pH. This study was then modified by another research group, 
attempting to make a dual functioning CD guest-host gatekeeper that could increase the toxicity 
of the MSNs by having the guest molecule be an anti-cancer reagent itself.25  
 Cleavable release 
Additionally, pH can cause changes in electrostatic interactions. So if a MSN is enveloped with 
a molecule through a charged based interaction, the drop in pH can disrupt the interaction thus 
releasing the drug, as shown in table 2.1.25 The most common approach to a pH dependent 
gatekeeper, however, is a molecule that is stable in a physiological pH of 7.4, but can be cleaved 
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under acidic conditions, such as that of a tumor or 
lysosome (illustrated in table 2.1). An example of this 
type of gatekeeper is described in the article published by 
The Royal Society of Chemistry, where a polymer bond 
to the MSN via an acid cleavable linker. The study utilizes poly(acrylic acid) homopolymer (PAA) 
to block the release of a well-known chemotherapeutic agent, doxorubicin (DOX).7 The acid 
cleavable linker chosen, whose structure is shown in Figure 2.1, was 3,9-bis(3-aminopropyl)-
2,4,8,10-tetraoxaspiro[5.5]undecane (ATU). ATU was linked via EDC/NHS coupling to MSNs 
that had previously been functionalized to 
contain a carboxylic acid group on their 
surface. Once the linker was attached the MSN 
was loaded with DOX and capped by allowing 
the MSNs to stir in a concentrated DOX for 
several hours, followed by the addition of PAA 
and EDC/NHS and stirred for several more 
hours. Control MSNs were also synthesized by 
attaching PAA directly to the MSN surface.7  
The drug release studies performed showed 
that the acid cleavable linker worked as 
intended. In Figure 2.2b, the MSNs without a 
gatekeeper (denoted DOX@MSN-COOH) 
exhibit spontaneous release at all pHs and the 
MSNs with PAA attached directly (denoted as 
Figure 2.1: Structure of the acid 
cleavable linker, ATU 
Figure 2.2: Release profiles of modified 
MSNs. a: profile for MSNs containing DOX and acid 
cleavable linked PAA. b: profile for control MSNs 
containing DOX. One without a gatekeeper and one 
without the acid cleavable linker.7 
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DOX@PAA-noACL-MSN) show little release 
regardless of pH. Above in Figure 2.2a, however, it 
is notable that the release of DOX increases with the 
decrease in pH. The highest percentage of release 
was at pH=4, but pH=5 was still three times that of 
the release at neutral.7 The MSNs were then studied 
in-vitro to observe cellular uptake and release of 
DOX. Using confocal laser scanning microscopy 
(CLSM), the hypothesis that the modified MSNs 
would be localized in the lysosomes was proven 
correct. Lysotracker Blue was used to label the 
lysosomes of nasopharyngeal carcinoma cells 
(HNE-1). DOX has its own red florescence. In 
Figure 2.3, it is obvious from the merged image that 
the MSNs are localized in the lysosomes. It is also clear 
that red florescence increases over time, before 
eventually exiting the lysosomes and entering the cytoplasm. With the control MSNs, however, 
the red florescence remained in the lysosome even after a 24h incubation period, suggesting the 
non-cleavable gatekeepers held DOX inside while the cleavable gatekeepers allowed its release.7 
Similarly, cells’ nuclei were dyed and CLSM was performed. The out was as expect, the DOX in 
the MSNs containing the cleavable linker reached the nucleus, while the DOX in the MSNs without 
the linker did not. Before moving to in-vivo studies, the cytotoxicity of the MSNs was determined 
using MTT assays. Both DOX loaded and unloaded MSNs were tested against HNE-1 cells. The 
Figure 2.3: In-vitro cellular uptake 
study. a: confocal imaging of MSNs containing 
DOX and acid cleavable linked PAA. b: 




unloaded MSNs showed biocompatibility, while the DOX loaded MSNs that contained the acid 
cleavable linker killed the cells substantially. The DOX loaded MSNs with the PAA directly 
attached showed 100%+ cell viability, continuing the proof of concept. Finally, an in-vivo 
experiment was conducted in which “HNE-1 tumor model bearing luciferase expressing activity”7 
was used. This allowed the scientists to observe the tumor using bioluminescent imaging while the 
mice were under anesthesia. With the various controls, the results were strikingly similar to that 
of the in-vitro testing. The DOX loaded, PAA gated MSNs that contained the acid cleavable linker 
were able to greatly reduce the growth of the tumor. They did not reduce the size as much as the 
free DOX, however, the weight loss of the mice was significantly less over the 6-day course when 
the mice had been treated with MSNs instead. This suggested the MSNs were overall less toxic 
and more targeted than the free DOX alone.7  
 Multi-function release 
Sometimes multiple methods of pH-based release can be employed into a single gatekeeping 
system.  A study done out of Northeast Normal University in Changchun, China, did this by not 
only modifying the CD gatekeeping system by placing tags on the CD cap, but also having the 
guest molecule attached to the MSN via a pH cleavable linker. The CD cap was tagged with two 
different molecules. One molecule was a targeting molecule, while the other was a florescent dye.27 
The guest molecule was attached to the MSN via a benzoic–imine linker that could be cleaved in 
acid conditions. The guest molecule itself was 1-adamantylamine, known for its anti-viral and 
other therapeutic effects. As a proof of concept, the MSNs were loaded with DOX.27 
The release study showed at pH=5.3 the drug almost 90% of the drug was released over the 
course of 72h. This was almost 3-fold better than that of pH=6.8 and was at least 8-fold of that at 
the physiological pH of 7.4 (Figure 2.4).27 As for the targeting agent used, either folic acid (FA) 
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or lactobionic acid (LA) were attached to 
the CD. With the multifunctional MSNs 
made, in-vitro studies were done. First, 
MTT assays were ran to determine 
cytotoxicity of the MSNs. The assays were 
ran for 24, 48, and 72h against HeLa cells. 
The major take away from the MTT assays 
was that the FA was a better targeting 
molecule, with cell viabilities being slightly 
lower than that of LA, and that when there is free FA available it will compete for binding.27 
Finally, confocal imaging was used to track the MSNs within HeLa cells. As expected, the FA 
tagged MSNs had the best cellular uptake. The imaging also showed that the florescence tagged 
CD caps remained in the cytoplasm while the DOX localized in the nucleus.27 Overall, this study 
showed how more than one pH-based release system can be incorporated into a single NP 
gatekeeper for enhanced drug delivery. 
 Light irradiation release  
Much like pH-dependent release, light irradiation can have multiple methods of release with 
the two most common being: photo-cleavable linkers and photothermal heating. Photo-cleavable 
linkers and photothermal heat for release have both been studied extensively. Taking their 
properties and incorporating them as MSN gatekeepers has opened the door for more diversity in 
release. Often, these methods are incorporated into dual- or even triple-stimuli release systems.  
Figure 2.4:In-vitro release study at varying pH. 
Release of DOX from multifunctional MSNs at varying pH 
over 72 hours.27 
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 Single stimulus release 
Near infrared light (NIR) is considered to have the deepest tissue penetrating ability, making it 
the most commonly used light for irradiation triggered systems. Recently, a gatekeeping system 
was developed utilizing reduced graphene (RGO) nanosheets as a capping agent. The system 
works by attaching alkyl chains to the MSN then loading with a model drug, DOX. These alkyl 
chains interact with the RGO through noncovalent interactions believed to be σ- π interaction and 
hydrophobic interaction.28 In this single stimulus release system, NIR light (780) is utilized to 
disrupt these interactions and release the DOX. As proof of concept, the system was tested in-vitro 
against human hepatoma SMMC-7721 cells.28 
First, a release study was performed to prove that 
the MSNs would release more efficiently at higher 
temperatures. This was first done in aqueous 
solution, increasing the local temperature. The 
results shown in Figure 2.5 clearly indicate that the 
expectation was correct with the release at 60oC 
being more than 6 times that of room temperature 
release.28 Next, to prove that these results could be 
achieved with NIR light, the MSNs were observed at room temperature under varying power 
densities of NIR light. Again, the results confirmed the hypothesis, with a higher cumulative 
release at the highest power density of 2 W/cm2.28 Using confocal imagining, they MSNs were 
tracked in-vitro. The lysosomes of the SMMC-7721 cells were dyed using Lysotracker blue and 
DOX was tracked from its red fluorescence. The cells were incubated with the RGO capped MSNs 
for 4h and 8h, then exposed to NIR irradiation with a power density of 2 W/cm2 for 5 minutes.28 
Figure 2.5: Release profile of RGO 
capped MSNs at varying temperature. 
MSNs were in aqueous solution.
28 
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From the imaging it was clear that the 
MSNs likely accumulate in the lysosomes 
prior to DOX being released with much of 
the merged fluorescence overlapping at 4h 
and the red being more spread across the 
cell at 8h. Unfortunately, CLSM was not 
performed on cells that had been exposed 
to the MSNs, but that had not been exposed 
to NIR light. MTT assays were performed 
to quantify the cytotoxicity of the MSNs 
before and after irradiation (Figure 2.6). 
The assays confirmed that the MSN+5min irradiation had higher cytotoxicity that that of the non-
irradiated group and the free DOX after 48h exposure to the MSNs/free DOX. The control group 
with concentration 0ug/ml showed that there was little death caused by the NIR irradiation itself.28 
These results proved that RGO could be used as a gatekeeper for MSNs with a triggered release 
from NIR irradiation. 
 Another single stimulus release system utilized the “light induced hydroxide ion emitter,” 
malachite green carbinol base (MGCB), to cause a pH jump which allowed release of cargo inside 
the MSNs. In this study, i-motif DNA where used as the capping agent. MGCB was immobilized 
in the channels of the MSNs. Ru(bipy)3
2+ molecules were loaded into the MSNs as a trackable 
dye.29 Without light irradiation the DNA remained folded and blocked the pore of the MSNs, once 
exposed to UV light the DNA would unfold due to the increased pH and the dye could be release 
(similar to depiction in table 2.1-d). The release study showed that while in the dark the MSNs 
Figure 2.6: Cell viability after exposure to 
RGOMSNs+NIR, RGOMSNs, and free DOX. 
SMMC-7721 cells incubated with varying concentrations for 
48h. NIR group irradiated for five minutes after 1h of 
incubation.28 
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only released about 10% of the dye over the course of 2h, but the MSNs exposed to UV light had 
a release of almost 90%.29 Unfortunately, UV light has very low tissue penetration, greatly limiting 
the applications of these NPs. 
 Multi-stimulus release  
In 2015, an article was published describing a dual-stimulus release system. The gatekeeper 
allowed differently sized cargo to be released by varying stimuli. The gatekeeper was again a 
guest-host system, only this time the CD cap was linked to the MSN by a photocleavable linker. 
The guest molecule was then chosen to a ferrocene.30 With this model, two cargos were loaded 
into the MSNs: small size cargo p-coumaric acid (CA) and large size cargo Calcein. Calcein was 
loaded first, then the CD caps were attached, followed by loading of CA, and finally the ferrocene 
guest molecule. As shown in Figure 2.7, the ferrocene interaction with the host molecules could 
be disrupted with 1.5V of 
electro stimulation. This 
allowed the smaller cargo, 
CA, which can fit through 
the channel of CD to exit the 
MSN, while the large cargo 
remained trapped inside.14 
Once CA no longer showed 
release, the MSNs were 
washed with di-water and 
exposed to UV light, cleaving 
the CD caps and allowing the 
Figure 2.7: Schematic illustration of dual stimulus, guest-host 
gatekeeping system. MSNs linked via a photocleavable linker to 
cyclodextrin (yellow), loaded with p-coumaric acid (red) and Calcein (green). 
Capped with ferrocene (blue).30 
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release of Calcein.30 This study shed light on the possibility combination therapy utilizing one NP. 
The biggest drawback is, as mentioned before, UV light does not have excellent tissue penetration 
limiting the use of these MSN in-vivo.   
Exploiting inorganic nanoparticles as gatekeepers for MSNs can have many advantages. Taking 
advantage of the pH change in the cell can reduce the NPs. Also, the NPs can be reduced by 
molecules naturally occurring in the body. Recently, J. Wen et al combined these characteristics 
with the photo sensitive molecule: hematoporphyrin (HP).25 The MSNs were loaded first with 
DOX then with HP. They 
were then capped with 
CeO2 NPs as the 
gatekeeper making a tri-
stimulus gated MSN. 
Once exposed to both the 
low pH environment 
within the tumorous cell 
and increased levels of 
glutathione (GSH), 
which is common in 
cancerous cells, the 
CeO2 would be reduced. This re-exposes the HP molecules which can undergo a conformational 
change under light irradiation thus allowing enhanced release of DOX and O2 production that has 
the potential for “photodynamic therapy” (illustrated in Figure 2.8).25 Overall, this study along 
with others gave examples of potential gatekeepers with photo-driven releases. The largest 
Figure 2.8: Schematic illustration of tri-stimulus gated MSN.25 
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disadvantage of these types of gatekeeper is the limitation of tissue penetration. The NPs are still 
exceedingly particle for the treatment of several diseases, but the breath of their scope is bound by 
this limitation. 
 Degradative release 
Degradative release is the broadest category of gatekeeper. This includes any gatekeeper which 
is broken down or disrupted do to the presence of an enzyme or molecule found within the cell. 
The most common molecule is GSH, but it is not the only one used in bioresponsive systems. Lipid 
envelopes can also fall under this category depending on the nature of their breakdown. The main 
issue involved with enveloping MSNs in lipid layers is they tend to aggregate, which could lead 
to decreased biocompatibility.31 Due to this, polymers, DNA templates, proteins/peptides, and NPs 
are more often explored. 
 Nanoparticle coating 
Typically, NPs used as gatekeepers are prepared and then attached to the MSNs via a linker 
molecule. An example of this was seen in the CeO2 gatekeeper described above. The CeO2 could 
be reduced in the presence of GSH and work as a single stimulus, bioresponsive gate keeper as 
well.24 One article described the use of DNA templating to form silver NPs (AgNPs) in-situ around 
the MSNs. This was accomplished by first functionalizing the MSNs with isocyanatopropyl 
groups, then grafting cytosine-rich DNA onto the MSN. Once the DNA template was in place the 
MSNs were loaded with a dye as a model drug, rhodamine 6G (Rh6G).32 Then AgNPs were formed 
on the surface on the MSNs by placing them in HEPES buffer with Ag+ ions in varying ratios. The 
TEM images make it clear that the more Ag+ present, the larger the NPs are both in size and 
quantity (Figure 2.9). The size difference in the NPs allowed for the cargo to be released with 
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varying amounts of 
GSH, thus allowing 
these gatekeepers to be 
“tuned” for treatment.  
This effect was better 
quantified by 
performing a release study.32 The capped MSNs were first placed in medium as a control and then 
the experimental group had 5.0mM of GSH added and the absorbance was read after incubation. 
Then a release profile was made by using different concentrations of GSH against all three NP 
gatekeepers. As expected the size of the AgNP gatekeeper inversely correlated to the amount of 
Rh6G release, shown in Figure 2.10.32 These study will need to investigate the in-vivo properties 
of the AgNP gated MSN before firm conclusions can be draw about their applications.  
Figure 2.9: TEM images of MSNs capped with Silver 
nanoparticles. a: ratio of 20:1 Ag+:MSN b: ratio of 40:1 Ag+:MSN c: ratio of 80:1 
Ag+:MSN.32 
Figure 2.10: Release studies of AgNP gated MSNs 
a: Absorbance spectra for varying size of AgNP gates. b: Release profile of the MSNs. AgNP-3@MSN correlates to 
the 80:1 ratio, AgNP-2@MSN correlates to the 40:1 ratio, and AgNP-1@MSN correlates to the 20:1 ratio.32 
22 
 When using NPs as gatekeepers, the NP does not 
need to break down or be reduced in order to remove it 
if it is bound to the MSN by a cleavable linker. One 
study explores this by using ATP aptamer as the linker. 
Aptamers will interact with a targer molecule, in this 
case ATP, and disrupt the connection between the NP 
gatekeeper and the MSN. The study utlized gold NPs 
(AuNP) functionaized with ATP aptamers. These were 
linked to the MSN by an adenosine molecule anchored 
to the surface of the MSN. When the target molecule 
was presence the aptamer bound to it releasing the 
AuNPs from the surface and allowing the model drug 
(fluorescene) to escape.33 TEM images show their 
proof of concept was successful. The AuNPs are bound closly to the MSNs without ATP present, 
and with ATP present few remain attached (Figure 2.11). The release studys gave the same results. 
They also tested if the gatekeepers were able to be triggered by other phosphate molecules 
including CTP, GTP, and UTP. From this is was confirmed that they gatekeepers were only 
triggered in the presence of ATP.33 Altogether, this study is an excellent example of fine tuning a 
gatekeeping system that can be triggered by a specific biomarker. In-vivo testing still needs to be 
conducted to confirm the system will work within the body, but it does appear promising.  
 Protein/peptide coating 
Proteins and peptides can wonderful gatekeepers due to their diversity. The peptide can undergo 
a conformational change or be cleaved once it is inside the cell. Proteins can do the same and can 
 Figure 2.11: TEM images of MSNs. 
a: MSNs with no modification. b: MSNs with 
adenosine anchors. c: MSNs with AuNP-aptamer 
cap. d: MSNs with AuNP-aptamer cap in the 
presence of ATP.33 
23 
potentially be used in targeting specific cells as well and are inherently biocompatible. An example 
of a protein use was done by Liu et al. where phenylboronic acid (PBA) was conjugated human 
serum albumin (HAS). PBA was used as a targeting molecule, while HAS was the bioresponsive 
linker. In the presence of MMP-2, which is commonly overexpressed in tumor cells, HAS would 
break down removing the gatekeepers and releasing the drug.25 This system was proven in in-vitro 
and in-vivo experiments.25 Several other protein gatekeepers have been investigated, along with 
the use of a disulfide linker. 
While proteins are biocompatible, they also often need to be isolated due to their complex 
nature. Instead, some scientists have chosen to investigate the use of peptides, or short strands of 
amino acids that often contain the crucial portions of the much larger proteins. To provide a brief 
example, the use of protease sensitive peptide was used as a gatekeeper. The peptide was long 
enough in length that when attached to the MSN its folded conformation blocked the pores of the 
MSN. The peptide was designed to have several spots that could be cleaved. Once a protease was 
introduced the peptide was cleaved in locations, allowing the drug to be release.25 This is one of 
the simplest examples. Peptides can be modified to only release in the presence of very specific 
enzymes, making them an advantageous gatekeeper for targeted delivery.  
 Polymer coating 
Polymers have also been explored as gatekeepers. This is not surprising considering polymers’ 
coating abilities. Typically, polymers are broken down by the cell and that is how the cargo gets 
released from the MSNs. This is not the only type of release the are capable of. With intention in 
design, polymers can be pH, temperature, irradiation, or even ultrasound sensitive. Looking closer 
at the biosensitive polymers, they are often broken down to the reducing environment within the 
cell, specifically due to GSH. Once the polymer gatekeeper is in place it can also have targeting 
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molecules conjugated to it. An 
example of this method noncovalently 
coated MSNs in “biocompatible self-
crosslinkable random copolymer   
containing pyridine disulfide 
hydrochloride (PDS) and poly-
ethylene glycol (PEG) as side chains”5 
using a one-pot method. PEG was 
added to increase water solubility of 
the NPs. Cyclic (Arg-Gly-Asp-D-Phe-
Cys) or cRGDfC was used as a 
targeting agent for cancerous cells and 
DOX was loaded as a model drug. The 
polymers broke down in the presence 
of GSH. The release studies, shown in 
Figure 2.12, proved that the more highly crosslinked polymers required more GSH to release the 
same amount of drug, allowing the MSNs to be customized to the treatment needs. After this, the 
polymer coating was tested on MSNs with a different morphology and the same result were 
observed.5 Next the polymer coated MSNs were tested against a human nasopharyngeal carcinoma 
cell line (KB cells). To do so, a targeting molecule decorated polymer and a non-decorated polymer 
were used to encapsulate MSNs. Then CLSM and an MTT assay were used to determine the 
effectiveness of these gatekeepers. The CLSM made it clear that the targeting molecule greatly 
increased the ability of the MSNs to enter the cells (clear from the increased red fluorescence). 
Figure 2.12: Release studies of polymer coated MSNs 
a: polymer coated MSNs in the presence of varying concentrations 
of GSH b: polymer coated MSNs with different crosslinking 
densities in the presence of 5mM.5   
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The MTT assay also reflected this showing a cell 
viability difference of nearly 20% at the highest 
concentration of MSNs. The cell viability assays 
can be seen in Figure 2.13.  similar results were 
observed when then MSNs were loaded with 
cisplatin in place of DOX.5 Overall, the in-vitro 
results of this study encourage more research of 
these tunable polymers coatings. They also 
emphasize why not only polymer gatekeepers, but 
degradative gatekeepers as whole are so diverse. 
 Summary 
As summarized in this chapter, gatekeepers can be extremely diverse. They can provide 
triggered release under an array of methods including pH changes, light irradiation, and response 
or degradation to specific molecules within the body. Within each of categories there is more 
diversity still. There is degradation, conformer change, cleavability and more. Each having its own 
set of advantages and disadvantages. pH dependence for example could still result in release in 
healthy cells due to the acid nature of lysosomes. Light irradiation is greatly limited by the 
penetration depth of the given wavelength, but that does not render it useless. It could, for example, 
be used to treat melanoma where the penetration depth would be more than adequate. As for 
bioresponsive gatekeepers, they can be triggered by specific molecules or enzymes that are over 
expressed in cancerous cells, but these are naturally occurring in healthy cells as well, making the 
system less than 100% failproof. All of these modifications, even with their flaws, have higher 
specificity that the commonly used chemotherapeutic agents available today. 
Figure 2.13: Cell viability assay of 
polymer coated MSNs. PMSN represents 
polymer coated MSNs that did not have the targeting 
molecule attached. RGD-PMSN are those that did 
have the targeting molecule attached.5 
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Through further investigation, it is possible to employ multiple of these methods into a single 
gatekeeper. A multi-stimulus system could improve specificity and biocompatibility further, 
creating an active targeting drug delivery system. The broader impact of these systems is not 
limited to cancer treatment. MSNs can be loaded with a variety of drugs, allowing them to treat an 
umbrella of diseases. The incorporation of smart gatekeepers could also allow drugs already used 
to be delivered with more accuracy, allowing smaller dosages to enter the body. Altogether, the 




Chapter 3 - MSNs Developed for Treatment of Bacterial Infections  
Recently in the Bossmann group a one-pot method for MSNs was developed by Dr. 
Hongwang Wang. The method dramatically increased the loading efficiency of the NPs and 
opened the door for new loading procedures. This chapter will discuss the fine-tuning of 
benzalkonium chloride containing MSNs, proposal and synthesis of novel surfactants, construction 
of MSNs around these surfactants, as well as a gatekeeping system. 
 Preliminary studies and relevant background 
 Benzalkonium Chloride MSNs 
 Synthesis 
To synthesize 100nm in diameter nanoparticles approximately 500mg of BAC is combined 
with 4.8ml NH4OH (28-30%), 20ml of ethyl acetate and 300ml of D.I. water. This was stirred at 
room temperature for 10 minutes until a clear solution formed. Then 500µl of tetraethyl 
orthosilicate (TEOS) was added while stirring vigorously. The reaction mixture was heated to 60oC 
and allowed to stir for 12 hours. Once the solution cooled to room temperature the white precipitant 
was collected using centrifugation (10000rpm, 10min), washed with approximately 5ml of D.I. 
water three times, and then washed with 5ml pure ethanol three times.  
Next MSNs with NH2-functionalized surfaces were synthesized. To synthesize 50nm 
nanoparticles 273mg of BAC was mixed with 350µl of 2M NaOH solution and added to 120ml of 
D.I. water. This solution was heated to 80oC while stirring for 30 minutes. Then a mixture of 700µl 
TEOS and 100mg (3-Aminopropyl)triethoxysilane (APTES) was added dropwise. The reaction 
mixture was allowed to stir at 80oC for 18 hours and then cooled to room temperature. Again, the 
white precipitant was collected using centrifugation (10000rpm, 10min), washed with 5ml D.I. 
water three times, and then washed with 5ml pure ethanol three times.  
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Changing the concentration of starting reagents and the length of time the reaction mixture 
was allowed to stir affected the size of the resulting MSNs. These MSNs were characterized using 
various methods. To remove the templating agent from them MSNs for control purposes, 500mg 
of the MSNs were stirred in a solution of 5ml of concentrated hydrochloric acid (HCl) and 45ml 
of absolute ethanol under reflux for 2 hours. The MSNs were then collected using centrifugation 
(10000rpm, 10min), and washed with D.I. water three times, and ethanol three times. The collected 
material was dried under high vacuum overnight and stored in a desiccator. 
 Characterization 
The morphology and size of the MSN samples were characterized by Transmission 
Electron Microscopy (TEM) and Scanning Transmission Electron Microscopy (STEM). The TEM 
samples were prepared by immersing carbon-coated 200-mesh copper grids in the solution MSNs 
followed by washing the grids with dropwise chloroform and dried overnight in a desiccator. High 
resolution TEM are recorded on FEI 
Tecnai F20XT, 200kV; FEI, Hilsboro, 
OR. The hydrodynamic diameter and the 
zeta potential of the MSNs were 
measured on a ZetaPALS zeta potential 
analyzer (Brookhaven Instruments 
Corporation) by hydrodynamic light 
scattering (DLS) and laser Doppler 
electrophoresis. DLS measurements were 
recorded directly on MSN aqueous 
suspension at neutral pH.  
Figure 3.1: STEM and TEM of BAC templated 
MSNs: (A) 100nm MSNs, (B) 250nm MSNs, and 
(C) 750nm MSNs. 
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Thermogravimetric analysis (TGA) of MSNs were performed on a Shimadzu TGA-50 Analyzer. 
Approximately 5mg of each sample was heated under a stream of dry nitrogen (10 mL/min) from 
25 °C to 700 °C at a heating rate of 5 °C/min. 
The BAC templated MSNs (BACMSNs) without NH2-functionalization were spherical in 
nature and had defined pores. Their size could be manipulated from 100 ± 15nm to 250 ± 20nm, 
and further to 750 ± 20nm by varying the concentration of BAC and/or silica precursor) of the 
BACMSNs were found to be 138 ± 10nm, 250 
± 15nm, and 741 ± 25nm respectively (Figure 
3.2. Surprisingly, the zeta potential revealed 
the nanoparticles to have a large negative 
surface charge (ranging from -20mV to -
50mV). This charge is not usually ideal for 
cell association. When attempting to load 
traditional MSNs with BAC, achieving high 
loading efficiency was difficult with the best 
results being around 1% (w/w). The BACMSNs however were found to have 16.2%, 19.2%, and 
23.1% for the 100nm, 250nm, and 750nm MSNs respectively when analyzed using TGA (Figure 
3.2). 
The spontaneous release was tested by adding 10mg of BACMSN to 10ml of Lennox broth 
(LB) and incubating at 37oC for 48 hours. The nanoparticles were collected using centrifugation 
(10000rpm, 10min), then washed with D.I. water. The recovered nanoparticles were lyophilized 
to dryness. By comparing the TGA results of the as prepared MSNs, we found 34.2%, 33.5%, and 
Figure 3.2: TGA of 100nm, 250nm, and 
750nm BAC templated MSNs. 
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42.5% of BAC leached out of the MSNs after 48 hours incubation for 100 nm, 250 nm, and 750 
nm MSN respectively (Figure 3.3). 
 
     Figure 3.3: TGA of BACMSNs before (blue) and after (orange) incubation in LB broth 
The APTES-added-BACMSNs were characterized in the same manner. The addition of 
APTES served to make functionalization of the resulting MSNs possible. It is necessary for 
introduction of functional moieties, such as gatekeepers, targeting antibodies, peptides, or dyes. 
The amino groups are usually graphed on the surface of MSNs by addition of APTES into MSN 
suspension under reflux condition. Once this reaction is complete the MSNs are washed several 
times to remove reactants. The BACMSNs, however, would lose BAC content during this process. 
That is why the APTES was mixed with the TEOS and used as one of the silica precursors. TEM 
and STEM characterization showed monodispersed spherical MSNs. The size of the particles again 
could be controlled by the concentration of BAC and/or silica precursors. By doubling the reactants 
concentration, the size of the particles was increased from 50 ± 5nm to 200 ± 10nm (Figure 3.4). 
Zeta potential measurements showed that the as synthesized MSNs possessed slightly positive 
surface charge which could be considered more ideal for a drug delivery vessel. A large positive 
surface charge was observed for acid-washed MSNs which confirmed the presence of amino group 
on the surface of MSNs prepared by this method. TGA showed the loading efficiency was over 
20% for both 50nm and 200nm sized MSNs (Figure 3.5). 
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Figure 3.4: TEM and STEM for BACMSNs featuring amino groups on their surface. 
 
Figure 3.5: TGA of BACMSNs featuring amino groups on their surface, before (blue) and 
after (red) acid wash. 
 
 In-vitro studies 
In-vitro testing began in the Bossmann lab. The BACMSNs were tested against 
Micrococcus luteus. This is a great module organism for multi-drug resistant bacteria because it is 
difficult to kill, but M. luteus is not considered dangerous to work with. A liquid culture of M. 
luteus was prepared by inoculating 100ml of LB with one isolated colony of M. luteus. The culture 
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was incubated at 37°C for 48 hours to allow growth. One solution of BACMSN, acid washed 
MSNs, and BAC only were prepared by dissolving 2mg of MSN or BAC in 10ml of D.I. water by 
sonication for 15 minutes at 25°C. These concentrated solutions were further diluted to obtain 
50ml of two lower concentrations of 0.005 and 0.003mg/ml MSNs or BAC. After, 500mg of LB 
broth and 250mg of agar were added to each solution. Control LB agar solution was also prepared 
with no MSNs or BAC added. These solutions were autoclaved at 121°C for 30 min under 15 psi 
of pressure.  Once cool enough to handle, the LB agar was poured into plastics petri dishes to let 
solidify. Plates were incubated at 37°C overnight to ensure they had not been contaminated. A 
liquid culture of M. luteus was diluted to 6x10-9 its original concentration. This was done to observe 
isolated, countable colonies. The petri dishes were inoculated using 100µl of the diluted solution. 
The dishes were incubated at 37°C for 48 hours to allow growth. After 48 hours of incubation, 
pictures were taken to compare growth, and isolated colonies were counted on the dishes that had 
growth. Growth was not observed at concentrations of 0.005mg/ml BACMSN and higher.  
The minimum inhibitory concentration or MIC of a drug is the minimum concentration 
needed to inhibit growth of bacteria. The MICs of the BACMSNs against several strains of bacteria 
were determined in the Wolschendorf lab at the University of Alabama, Birmingham. The 
experiment utilized an OD600 experiment. To test susceptibility towards nanomaterials, individual 
colonies from plates were transferred into 3ml of MH-broth. From here cultures were grown for 6 
hours while shaking at 37°C, then OD600-normalized in MH-broth to prepare the inoculum for 
the susceptibility assay. After preparing 2-fold dilutions in MH-broth on a 96-well plate, the 
nanoparticles reached a maximum final concentration of 250µg/ml to a minimum of 1.95µg/ml. 
The inoculum (OD600=0.002) was then added to the wells containing the nanomaterials for a final 
OD600 of 0.001. Test plates were incubated for 14 hours at 37°C. After which the bacterial growth 
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was examined by reading OD600 using a Cytation3 plate reader (BioTek). For measure of 
bactericidal activity, 5µl of the resuspended well-contents were spotted onto MH-agar and 
incubated overnight at 37°C prior scanning the plates with an Epson V800 Photo. Data were 
analyzed using Gen5 (v3.02) software (BioTek) and Excel. The results of this experiment can be 
summarized in the chart below (table 3.1). The BACMSNs had excellent results with 
Staphylococcus aureus, with MICs as low as 3.8µg/ml. Methicillin-resistant S. aureus (MRSA) 
also showed susceptibility with MICs ranging from 3.8-15 µg/ml. Unfortunately, Pseudomonas 
aeruginosa, gram-negative bacteria, showed no susceptibility to the drug. Although the MIC 
values were not as low as desired, the fact that Acinetobacter baumanii showed any susceptibility 
is exciting because A. baumanii is known for its multi-drug resistance. 
Collection# Strain MIC
1510 S. aureus 3.8
1511 S. aureus 3.8
1513 S. aureus 3.8
1515 S. aureus 3.8
1471 S. aureus (Newman) 3.8
1508 S. aureus  (MRSA) 15
1509 S. aureus  (MRSA) 15
1512 S. aureus  (MRSA) 7.5
1516 S. aureus  (MRSA) 15
1517 S. aureus  (MRSA) 7.5
1518 S. aureus  (MRSA) 3.8
1520 S. aureus  (MRSA) 7.5
1522 S. aureus  (MRSA) 7.5
1523 S. aureus  (MRSA) 15
1529 S. aureus  (MRSA) 15
1300 Pseudomonas aeruginosa 250
1301 Pseudomonas aeruginosa 250
1302 Acinetobacter baumanii 15
1303 Acinetobacter baumanii 63
1304 Acinetobacter baumanii 63
 
Table 3.1: The minimum inhibitory co centr tion (μg/ l) of BACMSNs against various 
strains of bacteria. 
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 Quaternary Amines 
 Single headed 
Due to the outcome of the BACMSN in-vitro studies, other surfactants with biocidal or 
antimicrobial properties were investigated, starting with single-headed quaternary amines. Single 
headed surfactants are the oldest known surfactants. Their use varies largely depending on the 
length of the hydrophobic tail. Single headed cationic surfactants can also have two tails. An 
example of the simple synthesis of a single head, single tailed surfactant is shown below in Figure 
3.6. This surfactant showed moderate activity toward Escherichia coli (gram-negative) and S. 
aureus. Surprisingly, this surfactant had great activity toward two different fungi species, 
Aspergillus flavus and Candida albicans. When the free hydroxyl group of the head was not 
present, like the surfactant depicted in Figure 3.7, activity toward fungi was lost and only low-
moderate activity against bacteria was observed, making it clear that the free hydroxyl group is of 
importance to activity.23,36 This also called into question the lengths of the hydrophobic chains. In 
both cases there appeared to be a “cut off” length, meaning that activity increased as the chain 
length increased to a point. This cut off appeared to 12 
carbons in length. Overall, single headed surfactants 
are some of the “simplest” surfactants, for this reason 
their activity is not spectacular and could likely be 
improved.   
 
Figure 3.6: Synthesis of Single head cationic surfactants containing free hydroxyl group. 
n=6, 10, and 14 for total chain lengths of 8, 12, and 16 hydrocarbons.23 
Figure 3.7: Structure of single 
head/double tailed cationic surfactants 
containing an amide. n=8, 10, and 14 for 
total chain lengths of 10, 12, and 16 
hydrocarbons.36 
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 Gemini Surfactants 
Double headed surfactants are considered the stronger, better versions of their single 
headed predecessors. They are generally symmetrical molecules giving them the name “gemini.” 
These molecules can be connected either with or without a spacer. Two types of gemini cationic 
surfactants were examined. Their structures are shown in Figure 3.8. They are close to the gemini 
equivalents to the two single head surfactants previously discussed.22,23 One clear difference 
between the two gemini surfactants is 
that in one the hydrophobic tail is 
increased and in the other the 
hydrophobic spacer is increased. Both 
increase the hydrophobic nature of the 
surfactant and thus increase their 
activity. The amide containing 
compound even possessed activity 
toward fungi. The cut off effect was still observed for the amide containing compounds, but not 
for the compounds containing free hydroxyl groups. This may be because the length of the spacer 
did not exceed 12 carbons, which appears to be the “sweet spot”. Again, it was observed that 
having a free hydroxyl group is superior for functionality making it a great candidate for further 
research.22,23 When changing the head group of a surfactant it is important that the head is not too 
rigid. It commonly accepted that head groups containing more polar molecules (oxygen and 
nitrogen) are more active. Amides, however, can vary depending on tail components.37 When 
increasing tail length, a common trend is observed. Increased tail leaded to a decreased MIC or 
better activity. Halogenated tails showed an increase in activity. The spacers for gemini surfactants 
Figure 3.8: Structure of gemini cationic surfactants. 
A. gemini cationic surfactants containing amide groups where n=5, 
9, and 13. B. gemini cationic surfactant containing free hydroxyl 
groups where x=1, 5, and 11 for total spacer lengths of 2, 6, and 
12.22,23 
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can vary greatly as well. Spacers containing esters, like PEG, are suitable for antimicrobial 
compounds.22,23,48 Double headed surfactants are not required to be symmetrical. Asymmetric or 
hetero-surfactants open the door to a plethora synthesizable compounds, which may lead to the 
discovery of stronger activity and better degradative abilities. This portion of the field is rapidly 
expanding as more attention is draw to the capabilities of double headed/two tailed surfactants. 
 Addition of semi-fluorinated carbon chains 
One drawback of the cationic surfactants like BAC or the gemini surfactants described above 
was their lack of strong activity toward P. aeruginosa, a gram-negative bacterium. Gram-negative 
bacteria are more difficult to kill due to their double membrane. Using P. aeruginosa as a model, 
one study explored changing the hydrocarbon chains of standard gemini surfactants to semi-
fluorinated carbon chains. The study found that the addition of the semi-fluorinated chains 
drastically decreased the MIC in comparison to the traditional surfactants.38 This strategy could be 
used and tested against other gram-negative bacteria to see if it is equally as effective. 
 Rational Design of Novel Surfactants and Cleavable Gatekeeper 
 Surfactant Library 
Taking into consideration the previous studies, a small surfactant library was proposed. 
The surfactant designs are located in Table 3.2. These designs combine the structure of BAC with 
new functional moieties that should increase the activity against gram-negative bacteria. In the 
preliminary studies it was observed that the free, terminal hydroxyl group increased the broad-
spectrum activity. For this reason, all surfactants, excluding surfactants G and H, include at least 
one of these moieties. Also, it was discussed that Gemini surfactants have been more effective than 
their single headed counter parts, to test this theory both the single headed and double headed 
surfactant pairs were proposed. The pairs will be surfactants A and B, C and D, E and F, and G 
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and H. Surfactants E-H will explore the use of semi-fluorinated chains in broad-spectrum 
applications. It was hypothesized that surfactants C and E-H will shed light on the importance of 
the free hydroxyl group versus the semi-fluorinated chain. Surfactant I would investigate a triple 






Table 3.2: Potential surfactant variants for small surfactant library. Chloride counter ions 
omitted. 
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 Gatekeeping System 
 After synthesis of the surfactants, the next logical step of the project would be to test their 
activity against multi-resistant bacterial strains. Then the surfactants with adequate activity would 
be incorporated into MSNs using a one-pot synthesis method modified from that of the 
BACMSNs. Finally, using the information gathered about gatekeepers the following peptide 
gatekeeper was proposed (Figure 3.9). The peptide contains two protease cleavage points. One is 
cleavable by cathepsin B and the other is cleavable by Matrix metallopeptidase 9 (MMP-9). The 
rational for these two cleavage points was that MMP-9 is often highly expressed in areas of 
inflammation which is the body’s first response to infection34. Cathepsin B is a well-known, 
cysteine protease35 which was chosen because it is found in the lysosomes of cells, including 
defense cells, which my take up the MSNs more rapidly. This is the “fail-space” plan, which 
increases the chance of release, even if the MSNs were to be endocytosed into the cell before 
cleavage of the gatekeeper occurred. The two cleavage points in the designed peptide are 
potentially able to be cleaved by either enzyme and other proteases that have weak affinity for the 
designed sequence. Typically, this non-specific trait may be disadvantageous, but in this case, it is 
an advantage because it increases the likelihood of release in the desired location because other 
proteases are upregulated during infection and/or pain. The peptide’s design includes vancomycin  
anchored to the N-terminus of the chain via the free carboxylic acid on vancomycin labeled in red 
 
Figure 3.9: Proposed gatekeeping system for anti-microbial MSNs containing protease 
cleavable, peptide linker. 
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in Figure 3.10. This large molecule is the 
major steric or “bulk” provider for the 
gatekeeper, keeping the cargo in place, but 
is also a well-known antibiotic that once 
cleaved can provide dual treatment. There 
have been documented cases when the free 
hydroxyl group of vancomycin was 
coupled with a peptide to improve drug 
activity39,40, therefore it is assumed that the 
vancomycin will retain its activity even if a small portion of the peptide chain remains attached. 
The opposite end of the peptide would be covalently anchored to the MSN surface. The final 
product would be MSNs containing newly synthesized surfactants, coated with the cleavable 
peptide gatekeeping system.  
 Using bioinformatic software the cleavage sequence for MMP-9 was determined to be Gly-
Pro-Ala-Gly–Lue-Ala-Gly-Ala (GPAG-LAGA) with the cleavage point indicated by the large 
dash. The cleavage sequence for cathepsin B was determined to be Gly-Lue-Ala-Gly–Lue-Val-
Gly-Gly (GLAG-LVGG). Then a combined, extended sequence with increased solubility was 
determined to be Gly-Ser-Lue-Ala-Gly–Lue-Val-Gly-
Pro-Ala-Gly–Lue-Ala-Gly-Ala-Gly-Ser-Gly 
(GSGLAG-LVGPAG-LAGAGSG). The prediction 
software predicted an amorphous structure that should 
allow easy cleavage by MMP-9 and cathepsin B 
(Figure 3.11).41 
Figure 3.10: Structure of Vancomycin. 
Figure 3.11: Predicted structure of 
protease cleavable linker. 
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 Materials and Methods 
 Surfactant Synthesis 
Of the proposed surfactants, four were successfully synthesized and characterized. These 
included SA, SB6, SB12, and SC. Two variant surfactants were also synthesized. These were 
denoted as Variant 1 (V1) and its Gemini counterpart, Variant 2 (V2). 
 Surfactant A (SA) 
Surfactant A was synthesized following a method adapted from S.M. Shaban et al. (2016), 
in which 0.007mol N-benzylamino ethanol (N-BAE) and 0.021mol 1-bromododecane were 
dissolved in 100ml of absolute ethanol. The solution was refluxed for 24 hours. The solvent was 
then removed via rotovap. The yellow precipitate, N,N-didodecylbenzyl-2-hydroxyethan-1-
aminium bromide, was washed two times with 5ml diethyl ether. After washing the precipitate 
was white. The product was recrystallized in ethyl acetate. The reaction scheme is shown below 
in Figure 3.12.  
Figure 3.12: Reaction scheme for Surfactant A 
 Surfactant B-6 (SB6) 
Again, a method adapted from S.M. Shaban et al. (2016) was employed. This time 2.285ml 
of 1-bromododecane and 0.755ml of 1,6-dibromohexane were dissolved in 35ml of absolute 
ethanol and brought to approximated 80oC before adding 1.4ml N-BAE was added. The solution 
was the brought reflux and allowed to stir for 72 hours. After cooling to room temperature, the 
solvent was removed under vacuum and the gel like product, N,N'-bis(2-hydroxyethyl)-N,N'-
dibenzyl-N,N'-didodecylhexan-1,6-diaminium bromide, was rinsed with diethyl ether. 
Recrystallization was attempted using a variety of solvents, all of which failed to recrystallize at 
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room temperature and at 0oC. So, the product was left slightly impure. The product was orange in 
color and gel-like. 
 Surfactant B-12 (SB12) 
SB12 was synthesized following the same method described for SB6, but using 2ml of 
1,12-dibromododecane in the place of 1,6-dibromohexane to produce N,N'-bis(2-hydroxyethyl)-
N,N'-dibenzyl-N,N'-didodecyldodecan-1,12-diaminium bromide (SB12). The product was a deep 
orange in color and gel-like. 
 Surfactant C (SC) 
SC was synthesized by dissolving 0.015mol of 1-bromododecane and 0.015mol of benzyl 
bromide in 50ml absolute ethanol. Once the solution was approximately 80oC and the solution was 
clear, 0.01mol of diethanol amine was added while stirring rapidly. The solution was brought to 
reflux and stirred for 48 hours. Once cool the solvent was removed under vacuum, the product was 
washed with diethyl ether, and then placed on the vacuum line overnight. Again, the product was 
a gel-like substance and light orange in color. 
 Variant 1 (V1) 
Due to the reagents available a variant surfactant 
was synthesized by dissolving 960μl diethanol amine and 
1-bromododecane in excess in 50ml of acetone. The 
solution was refluxed for approximately 72 hours while 
stirring. Once the solution was cool, the solvent was 
removed under vacuum and the product was rinsed with 
diethyl ether. The product was yellow in color and 
resembled dish soap.  
Figure 3.13: Structure of Variant 
Surfactant 1 (V1). 
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 Variant 2 (V2) 
For synthesis of V2, 0.01mol of 1-
bromododecance and 3.7mmol of 1,12-
dibromododecane were dissolved in 50ml 
absolute ethanol. Then 0.0151mol of diethanol 
amine was added to the flask. The solution was 
brought to reflux and stirred for 24 hours. Once 
the solution was cool, the solvent was removed 
under vacuum and the product was rinsed with 
diethyl ether. Again, the product was a translucent 
gel, but this time was slightly opaque. 
 MSN Synthesis 
As proof of concept, MSNs were first constructed around V1. V1 was chosen because it 
had better water solubility than other synthesized surfactants and had moderate activity against 
Micrococcus luteus. In 100ml diH2O, 275mg of V1 was dissolved and 0.35ml 2M NaOH was 
added. This was stirred at 80oC for 20 minutes. Then 700μl TEOS was added and the solution was 
stirred overnight. The cloudy white precipitate that formed was collected via centrifugation 
(10min, 10000rpm), then washed 3 times with 5ml of diH2O. The product was then suspended in 
10ml of diH2O using sonication and frozen prior to being lyophilized.  
The MSNs were also synthesized using a modified Tween 80 procedure. The a 5mg/ml 
surfactant in diH2O solution was made. Then 5ml of this solution was placed in a flask with 1.5ml 
of 0.01M NaF. This solution was diluted to 50ml with diH2O and heated to 60
oC. This solution 
was stirred for 15 minutes to allow for the formation of micelles. Then 500μl TEOS was added 
Figure 3.14: Structure of Variant 
Surfactant 2 (V2). 
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dropwise. The solution was stirred for approximately 18 hours. Then the cloudy white precipitate 
was collected via centrifugation (10 minutes, 10000rpm). The precipitate was washed three times 
with 5ml diH2O and three times with 5ml ethanol before being lyophilized. 
 Acid Wash Procedure 
For controls, the MSNs were acid washed to remove the surfactant templates. This was 
done by taking approximately 30mg of the MSN and suspending them in a solution of 4ml absolute 
ethanol and 1ml concentrated HCl. This was refluxed with stirring for two hours. Once cool, the 
MSNs were collected via centrifuge (10min, 10,000rpm) then washed three times with diH2O 
before being lyophilized. 
 Gatekeeper Synthesis 
The gatekeeping system was synthesized by first synthesizing the peptide chain. This was 
done using solid phase peptide synthesis (SPPS). An insoluble resin loaded with glycine was 
swollen in methylene chloride (DCM). After removing the resin was then washed with 5ml of 
dimethylformamide (DMF). The first amino acid (F-moc protected) to be added, which is the 
second in the chain was weighed in a 1:3 molar ratio to the resin and HBTU, the coupling agent, 
was weighed in a 1:2.9 molar ratio to the resin. These were dissolved together in approximately 
8ml of 1:23 N,N-Diisopropylethylamine (DIEA) in DMF and added to the peptide synthesis tube. 
This was swirled at room temperature for a half hour. Then drained and repeated. After the second 
half hour, the resin which now contained a two-peptide change was rinsed five times with 3-5ml 
DMF. Then 4ml of 20% diethylamine in DMF, the F-moc cleaving reagent, was added to the tube 
and swirled for 1 minute then drained. Another 4ml of 20% diethylamine was added and this time 
swirled for 10 minutes and drained. The resin was the carefully rinsed with DMF five times before 
adding the next amino acid in the same manner as the first. This process was repeated for each 
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amino acid in the chain from left to right until the chain read GSGLAGLVGPAGLAGAGSG-
Resin. 
Vancomycin contains a free carboxyl acid group. Taking advantage of this vancomycin 
was dissolved in a 1:2 ration in 1:23 DIEA in DMF with 1:2.9 ratio of HBTU. This was allowed 
to stir was the final F-moc group was removed from the N-terminal of the peptide. After the peptide 
chain was rinsed carefully with DMF the solution was added and allowed to stir overnight. Once 
the reaction was complete the solution was removed, and the peptide chain was washed five times 
with DMF and then five to six times with DCM before adding the resin cleaving cocktail (95% 
trifluoroacetic acid, 2.5% TIPS buffer, and 2.5% diH2O). The cocktail was allowed to swirl for 3 
hours. During this time the resin and all side chain protecting groups were removed. The solution 
was then squeezed into 10ml cool diethyl ether. The precipitate was collected via centrifugation 
(10min, 10000rpm) and washed three times with cool diethyl ether before being dissolved in 10ml 
of diH2O and lyophilized. The vancomycin containing peptide was characterized by HPLC and 
mass spectroscopy.  
 Dynamic Light Scattering (DLS) and Zeta Potential 
The hydrodynamic diameter and the zeta potential of the MSNs were measured on a 
ZetaPALS zeta potential analyzer (Brookhaven Instruments Corporation) by hydrodynamic light 
scattering (DLS) and laser Doppler electrophoresis. DLS and Zeta potential measurements were 
taken of MSNs in aqueous suspension at neutral pH. Generally, for DLS, 50μl of a 1mg/ml stock 
would be diluted to 1ml using double distilled water and then read. For Zeta potential 50-80μl of 
a 1mg/ml sample stock would be diluted to 1.4ml using double distilled water before inserting the 
meter for reading. 
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 Thermogravimetric Analysis (TGA) 
 The TGA of MSNs were performed on a Shimadzu TGA-50 Analyzer. Approximately 
5mg of each sample was heated under a stream of dry nitrogen (10 mL/min) from 25 °C to 700 °C 
at a heating rate of 5 °C/min. The data was converted from milligrams lost to weight percent lost. 
 Transmission Electron Microscopy (TEM) and Scanning Transmission Electron 
Microscopy (STEM) 
TEMs and STEMs were carried out in the Microscopy and Analytical Imaging Laboratory 
at University of Kansas with the assistance of Dr. Prem Thapa. Several images were taken for each 
sample. 
 Bacterial Studies 
For studies against Micrococcus luteus the experiments were set up by dissolving the 
surfactant at varying concentrations into 25g/L Lysogeny broth (LB) containing 1% Agar. Then 
the solution was autoclaved (121 C, 20 minutes) and poured into plastic petri dishes. Each 
concentration had three replicas made. Once cool, 10μl cultured M. luteus was spread on the 
surface and incubated at 37oC for 48 hours. Colony forming units (CFUs) where then observed. 
For the purposes of these trials, growth was denoted as “+” and no growth was “-” and counted as 
“+” if any of the replicas showed growth. 
For studies against methicillin-resistant Staphylococcus aureus (MRSA), the surfactants 
were sent to our sent to our collaborators at UAB and performed in the same manner described in 
Chapter 3 – Relevant Background and Studies. Minimum inhibitory concentrations were reported 
in mg/ml. These studies were performed in solution. 
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 High Performance Liquid Chromatography (HPLC) 
Peptide purity was determined using HPLC (Ultimate 3000, Thermo scientific). The crude 
peptide was dissolved in distilled water at a concentration of 1.0 mg/ml. After running a blank, 
20μl of the solution was filtered using 0.2μM nylon filters and then injected into the HPLC column 
(Thermo AcclaimTM 300, C18, 3μm, 2.1 x 150mm). The flow rate was maintained at 0.30 mL/min 
using a binary mixture. A: water containing 0.10% TFA, B: acetonitrile with 0.10% TFA. 
Gradient: 1-16min: 20% - 80% B, 16-20min: 80% B. The wavelength used was 205nm. 
 Results and Characterization 
 Surfactants 
 NMR 
1H-NMRs were collected for each surfactant and can be seen in Appendix A. The spectra 
were compared to the simulated NMRs. The real NMRs were slightly shifted due to micelle 
formation, even in DMSO, and also had a few peaks that were due to the protons being different 
environments within the micelles and the ones that may have truly been free in solution. There 
were also small peaks near 9ppm in some of the spectra. These were assumed to be due to water 
that associated with the molecules.  
 Fourier-transform infrared spectroscopy 
FTIR was also taken for each surfactant. The FTIRs were used to confirm the functional 
groups present in the surfactant. Below is the FTIR for SA. The spectrum is not extremely clean, 
but an alcohol peak can be seen at 3300cm-1 and the aromatic region is correct. The typical bromo-
alkane peaks are also not obviously present, suggesting the starting material is not present. 
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Figure 3.15: IR Spectrum of Surfactant A. 
 Mass Spectroscopy (MS) 
Mass spec. was also used to characterize the surfactants synthesized. MS was performed 
by the Core Center at University of Kansas Medical. The calculated molecular weights are shown 
in the table below. The mass spectra for each surfactant gave the expected molecular peak which 
are shown in the figures following the molecular mass table. The fragmentation peaks also 
confirmed the molecules synthesized where the desired products. 
Surfactant Calculated Molecular Weight with 
Counter Ions 
Calculated Molecular Weight 
without Counter Ions 
SA 568.75g/mol 488.85g/mol 
SB6 883.01g/mol 723.21g/mol 
SB12 967.17g/mol 807.37g/mol 
SC 444.49g/mol 364.59g/mol 
V1 522.68g/mol 442.78g/mol 
V2 875.03g/mol 715.23g/mol 





Figure 3.16: Mass Spectroscopy Data for Surfactant A. 
 
Figure 3.17: Mass Spectroscopy Data for Surfactant SB6. 
Figure 3.18: Mass Spectroscopy Data for Surfactant SB12. 
 
Figure 3.19: Mass Spectroscopy Data for Surfactant C. 
 
Figure 3.20: Mass Spectroscopy Data for Surfactant V1. 
 
Figure 3.21: Mass Spectroscopy Data for Surfactant V2. 
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 Bacterial Studies 
The results for various surfactants against M. luteus are summarized in Table 3.3. As 
expected the Gemini surfactants SB6, SB12, and V2 had the best activity. This confirmed the 
assumption that Gemini surfactants have increased activity. The synthesized surfactant with the 
best activity was SB12 which showed activity at concentrations as low as 0.01mg/ml against M. 
luteus. It was assumed that surfactants that did not kill at 1.0mg/ml would not kill at lower 
concentrations. The 1.0mg/ml trials were repeated twice to ensure growth was observed and then 
further concentrations were not tested. 
Table 3.4: Activity of Synthesized Surfactants Against Micrococcus luteus.  
Growth indicated as “+” and absence of growth indicated as “-”. 
 
The surfactants were then sent to UAB for testing against MRSA. The MICs against MRSA 
directly correlated to those against M. luteus. SA and SC showed the lowest activity and SB12 and 
         1.0mg/ml 0.5mg/ml 0.3mg/ml 0.1mg/ml 0.05mg/ml 0.01mg/ml 0.005mg/ml 
SA +* + + + + + + 
SB6 - - - + + + + 
SB12 - - - - - - + 
SC +* + + + + + + 
V1 - - - + + + + 
V2 - - - - - + + 
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V2 showed the best activity. Unfortunately, the best activity was still approximately 10 times that 
of the common MRSA treatment, Vancomycin.42  
Table 3.5: Minimum Inhibitory Concentrations of Synthesized Surfactants against 
Methicillin-Resistant Staphylococcus Aureus. 
 
 Gatekeeping System 
Of the gatekeeping system, the peptide linker was successfully synthesized and an 
attempt to bind it to vancomycin was performed.  
 HPLC 
The HPLC of the crude peptide indicated that the purity of the peptide would be good 
enough to move forward to the anchoring of MSNs. There were minor impurities, but the presence 
of one major peak indicated the successful synthesis of the peptide and coupling of vancomycin. 
Figure 3.22: HPLC of Gatekeeping Peptide Linker Attached to MSN. 
 SA SB6 SB12 SC V1 V2 
MIC 
(mg/ml) 




 Mass Spectroscopy (MS) 
MS was used to determine if vancomycin had truly been attached to the peptide chain. 
Using a molecular weight calculator at genscript.com the molecular weight of the peptide without 
vancomycin was determined to be 1468.62g/mol (C62H102N19O22). The molecular weight of 
vancomycin is 1449.3g/mol. Considering that the coupling occurs with a loss of water, the final 
molar mass was expected to be 2899.84g/mol. The LC-MS showed a major peak around 940. This 
was not anticipated, but the peak near 2878.46g/mol indicated the desired product after the loss of 
one terminal glycine unit. This implied vancomycin had successfully been attached to the peptide. 










Figure 3.23: Mass Spectroscopy Data for Vancomycin Conjugated Peptide Chain 
 
 MSNs 
MSN characterization is accomplished using several methods. For the purposes of these 
studies TGA, DLS, Zeta potential, and TEM. These analyses confirmed the presence of a silica 
scaffold, as well as incorporation of surfactant.  
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 TGA 
The TGA of the MSNs catalyzed by either NaOH or NaF showed differing weight loss 
patterns. This was the first indication that the morphology of the two samples may be different. 
Both MSNs had patterns that appeared to follow the weight-lost pattern of the surfactant alone. 
This was good indication that V1 had successfully been incorporated into the mesoporous 
structure.  
 V1MSNs catalyzed with NaOH 
In Figure 3.16, the first notable feature is the solvent loss from 0-100oC. The next is that 
there is a distinct difference between the control MSNs and the V1-MSNs. This indicated loading. 
Finally, in the temperature range 100-400oC the V1-MSNs follow the same pattern as V1 alone. 
This suggests that V1 is what is loaded into the MSN structure. From the data collected, the weight 
Figure 3.24: TGA of NaOH Catalyzed V1-MSNs, V1 alone, and Acid Washed Control 
MSNs. 
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percent lost can be calculated. Using the control measurements, a “truer” calculation can be made. 
These calculations are summarized in Table 3.5. The loading efficiency was over 20% (w/w).  
 V1MSNs catalyzed with NaF 
Again, the same statements held true for the TGA of NaF catalyzed V1-MSNs. One notable 
feature present in V1-MSN-Fs and their control counterpart had a weight loss at approximately 
500oC. This was evidence that V1-MSN-Fs have a different morphology than V1-MSN-OHs. The 
weight lose pattern that correlated to V1 was much smaller, showing a lower loading efficiency 
(Figure 3.17). The calculations summarized in Table 3.6 agree with this, giving a loading 






Table 3.6: Summarized Calculations for TGA of TGA of NaOH Catalyzed V1-MSNs, V1 




Table 3.7: Summarized Calculations for TGA of NaF Catalyzed MSNs, V1 Surfactant 
Alone, and Acid Washed V1-MSN-F Control. 
 
Figure 3.25: TGA of NaF Catalyzed MSNs, V1 Surfactant Alone, and Acid 




Not surprisingly, the DLS results for the two types of MSNs varied greatly. Both exhibited 
sizes larger than expected, which may be due to aggregation.  
 V1MSNs catalyzed with NaOH 
The DLS reveled two distinct 
populations for the NaOH catalyzed MSNs 
seen in Figure 3.18. The first population was 
around 430nm in diameter. The other 
population was around 1200nm in diameter. 
This was assumed to be due to clustering of 
2 nanoparticles together (400nm*3 =  
1200nm). Although, these assumptions could 
not be verified without use of TEM. 
  
 V1MSNs catalyzed with NaF 
There was only on population for the 
NaF catalyzed MSNs. This can be seen in 
Figure 3.19. The population had a massive 
diameter size of approximately 4100nm. This 
was assumed to be due to aggregation rather 
than being the true diameter of the 
nanoparticles.  
 
Figure 3.26: DLS Results for NaOH Catalyzed 
V1-MSNs. 
Figure 3.27: DLS Results for NaF Catalyzed 
V1-MSNs. 
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 Zeta Potential 
Zeta potential is the measurement of the surface charge of the nanoparticle. When the zeta 
potential is either greatly positive or greatly negative less aggregation generally occurs. This 
observation has been made many times in the Bossmann Laboratory. 
 V1MSNs catalyzed with NaOH 
The Zeta potential for the NaOH catalyzed MSNs was negative, but with an average of 
only around -20mV it is reasonable to believe some clustering can take place. The Zeta potential 
graph, as well as the individual run readings and average can be observed in Figure 3.20.  
Figure 3.28: Zeta Potential Results for NaOH Catalyzed V1-MSNs. 
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 V1MSNs catalyzed with NaF 
The Zeta potential for the NaF catalyzed MSNs was nearly neutral with an average of 
3.66mV. The neutral surface charge could explain the aggregation that lead to the extremely large 
diameter reading from DLS. The graph and individual trial runs fort Zeta potential can be seen in 
Figure 3.21. 
Figure 3.29: Zeta Potential Results for NaF Catalyzed V1-MSNs. 
 
 TEM 
TEM and Scanning TEM (STEM) were used to visualize the structural differences between 
the NaOH catalyzed and NaF catalyzed MSNs. The results also were used to determine porosity 
and aggregation. 
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 V1MSNs catalyzed with NaOH 
The TEM images revealed that the NaOH catalyzed V1MSNs had a spherical shape and 
were approximately 20-50nm in size which can be seen in Figure 3.22 and Figure 3.23. The MSNs 
greatly aggregated. They also localized into secondary structures resembling bubbles. It is 
speculated that this was due to the 
surfactant being released and 
forming bubbles while sonicated 
that the MSNs clung to. The STEM 
showed that these structures were 
porous as expected. Overall, these 
TEM results were what was 
desired. The only surprising 
outcome was the amount of 
aggregation. From the Zeta 
potential it was expected that the 
MSNs would aggregate less. 
Figure 3.30: TEM of V1MSN-OH and Secondary 
Structures 
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Figure 3.31: TEM of V1MSNs Catalyzed by NaOH 
Figure 3.32: STEM of V1MSNs Catalyzed by NaOH 
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 V1MSNs catalyzed with NaF 
The TEM images for V1MSN-F had two different morphologies present. There were 
structures that resembled mesh (meso-mesh) and then there were large spheres. The meso-mesh 
Figure 3.33: TEM and STEM of the Mesh-Like Mesoporous Silica Nanostructures, “Meso-
Mesh” of V1-MSN-F. 
was porous when looking at the STEM. This is clear from the black pores showing thought the 
white structure. The clusters of meso-mesh varied in size from under 50nm to 2μm. The 
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nanospheres ranged in size from 400nm to 2μm. Looking closely at the edge of the spheres it is 
believed they may be porous as well. The spherical structures were anticipated, but the meso-mesh 
was not. Looking at the mesh, it is possible that several tiny nanoparticles are clustering together. 
This would not be as surprising given that the zeta potential was relatively neutral, which can lead 
to aggregation. These TEM images also confirm that the large diameter readings were due to 
aggregation as the particle size was not uniform and no single particle had a diameter of 4000nm. 
Aggregation is not surprising because the Zeta potential was nearly neutral. The nanospheres are 
larger than anticipated as well, but this may be able to be fine-tuned by changing the concentration 
of surfactant to begin the reaction. This is what was done for the BACMSNs and worked nicely.  
 Discussion 
In this chapter the synthesis of four novel surfactants, their MICS, and their incorporation 
into mesoporous nanostructures was discussed. The results indicated that the expected surfactants 
had been synthesized. These surfactants had low to moderate activity against MRSA, with the best 
activity being that of SB12 at 0.027mg/ml. V1 was successfully incorporated into MSNs of two 
 Figure 3.34: TEM images of spherical nanostructures within V1-MSN Sample.  
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different morphology. The NaOH catalyzed synthesis resulted in much lower yields, but had less 
aggregation, a high loading efficiency, and a more uniform structure. NaOH synthesized MSNs 
had spherical, porous structures that aggregated in bubble like secondary structures. The NaF 
synthesized MSNs had both mesoporous mesh-like structures (meso-mesh) and more uniform 
spheres. The meso-mesh and nanospheres both varied in size. The synthesis of the gatekeeping 
system for these MSNs was also discussed. Considering this synthesis is a new method, it is not 
surprising that it did not turn out exactly as anticipated. Luckily, it has been observed that 
manipulation of the starting reagents can greatly affect the size of the resulting structures. 
Therefore, with some fine-tuning, the desired size and uniformity should achievable.  The di-
cleavable peptide was successfully synthesized. Vancomycin was also successfully anchored to 
the N-terminal using a newly established method.  
 Future Work 
Moving forward with the project, the gatekeeping system will be anchored to the surface 
of BACMSNs as proof of concept. Once the system is anchored the gated MSNs will be tested 
against M. luteus in solution to determine if the system is successful. Two versions of the peptide 
without Vancomycin will also be synthesized and anchored to the MSN to determine if the peptide 
alone will act as a gatekeeper. Vancomycin will also be anchored to the “cleaved” peptide variants 
to prove it is still active with these peptides attached. These MSNs are hoped to be applied to 
modern medicine in several ways including use as oral antibiotics and as preventive, slow-release 
antibiotics that can be placed at the site of surgery to protects patients for days or weeks to come.  
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Chapter 4 - MSNs Developed for Cancer Treatment 
Previously in the Bossmann laboratory an anti-cancer peptide was developed by Dr. Jing 
Yu. Due to its non-specific nature MSNs were implemented as a carrier vessel. Unfortunately, the 
loading efficiency was extremely low. In chapter the history of the peptide and its uses, various 
methods of building the MSN directly around the peptide, and creating a gatekeeping system will 
be discussed. 
 Preliminary studies and relevant background  
 Development of SA-K6L9-AS 
The predecessor of SA-K6L9-AS was an antimicrobial peptide developed in 2002 as an 
antimicrobial peptide called K6L9.
43 The name referred to the six lysine and nine leucine residues. 
The hydrophobic and polar nature of the peptide allowed it to disrupt the membranes of both gram-
positive and gram-negative bacteria in-vitro in a serum-free environment. The peptide was 
virtually inactive in the presence of enzymes Trypsin and Proteinase K which quickly broke down 
the peptide.43 With this in mind, the group chose to synthesize and test several diastereomers of 
K6L9 with varying amounts of D-amino acids. D-amino acids are not naturally occurring, so they 
often are more stable in physiological conditions. The best diastereomer was the peptide they 
called D-K6L9 with the structure LKLLKKLLKKLLKLL-NH2 where the D-amino acids are 
denoted by italics and underline.44 D-K6L9 appeared promising due to both its activity toward four 
gram-positive and four gram-negative bacteria in serum and its stability. It was determined that 
the mechanism of action was through membrane depolarization.44 This discovery implied that the 
peptide may be active toward more than bacteria alone. Thus, leading to the investigation of D-
K6L9 against cancerous cell lines.  
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A known trait of cancerous cells is that they exhibit a negative change on the surface of the 
membranes while healthy cells do not.44,45 There are two reasons thought to be the main 
contributors to this occurrence: enrichment of phosphatidylserine in the outer membrane leaflet 
and secretion of lactate anions due to the Warburg effect.45-47 The enrichment of 
phosphatidylserine helps the cancer cells avoid detection from the immune system because these 
molecules are non-immunogenic.44 One of the most notable differences in the metabolism of 
cancer cells is the elevation glycolysis and less reliance on mitochondria for production of ATP.45 
The byproduct of glycolysis is lactate, which is then excreted by the cell. This excretion of lactate 
leads to the negative cell on the surface of the cell, as well as the acidic environment found within 
tumors.45 A depiction of the secretion of lactate anions can be seen below. The negative charge 
allows for the cancer cells to be targeted by molecules containing positive residues/charges. 
 
Figure 4.1: Illustration depicting the upregulation of glycolysis and the subsequent 
extraction of lactate leading to a negative charge in cancerous cells.45 
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By 2006 it was established that D-K6L9 was active against multiple types of cancer, 
however the peptide was not selective and killed healthy cells showing systemic toxicity.43,44 
Confocal imaging using CL1 pancreatic cancer cells and a fluorescent dye was utilized to 
determine the mechanism of cell death. From the images in figure 4.2, it was determined that the 
peptide was interacting with the membrane of the cells, further proving the group’s proof of 
concept.43 Further, it was believed that cell death occurred through a necrotic mechanism because 
of data obtained from histopathology and cell permeability studies. D-K6L9 was able to depolarize 
the transmembrane potential and rupture the membrane. This was clear from release of a cell 
encapsulated dye into solution.43 
 
Figure 4.2: Confocal microscopy images of CL1 pancreatic cancer cells after 2 min., 3 min., 
and 5 min. of incubation with rhodamine-labeled D-K6L9.42 
Using the information discovered by Shai, et al. Dr. Jing Yu of the Bossmann laboratory 
at Kansas State University sought to enhance the properties. According to recent studies, it was 
determined that necrotic cell death is an advantageous in killing cancer cells because the release 
of cancer neoantigens which can be recognized by dendritic cells can trigger an immune 
response.48-50 A more through explanation of the cancer-immunity cycle can be found in Appendix 
B. The improvement of D-K6L9 aimed to amplify the necrotic mechanism and toxicity of the 
therapeutic peptide by increased targeting of organelles.51 Along with this, increased solubility and 
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the ability to differentiate the lysine and leucine residues via NMR were also desired. This was 
accomplished with the addition of four amino acids to the peptide change: a serine and an alanine 
on each end. The new chain read SA-LKLLKKLLKKLLKLL-AS. Through extensive NMR studies 
it was determined that SA-D-K6L9-AS did not retain an alpha-helical structure as predicted by 
software, in contrast it was much more amorphous shown in figure 4.3.51 
The toxicity of the improved peptide was then tested. As expected the toxicity had 
increased dramatically, being eight times more toxic to GL26 cells than D-K6L9. Using confocal 
imaging it was determined that this increased toxicity came from the ability of the peptide to also 
target the mitochondrial membranes as well. This was clear from the overlapping fluorescence 
B 
Figure 4.3: A. Predicted Folding of SA-D-K6L9-AS structure, as calculated by PEPstrMOD 
B. Most Probable Folding of SA-D-K6L9-AS in DMSO(D6) based on lowest number of NOE 
violations and a total energy as calculated by CNS.51 
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from the dye attached to the peptide and the dye that stained the mitochondria (figure 4.4). D-K6L9 
only was able to target the cell membrane.51 This also increased necrotic cell death which should 
benefit the cancer-immunity cycle. Unfortunately, the peptide remained unselective in its 
targeting, making a nanocarrier necessary. 
 
 Proposed Gatekeeping System for Anti-Cancer MSNs 
As well established within this thesis it is well known that MSNs exhibit a slow release of 
their cargo over time. Due to the unselective nature of SA-D-K6L9-AS this is not desirable. To 
combat this, a gatekeeping system was proposed. In this system, the MSNs loaded with peptide 
would first have iron oxide nanoparticles imbedded in polyvinylpyrrolidone (PVP) and dopamine 
Figure 4.4: Fluorescence microscopy of GL26 stained with Mitotracker Green FM, treated 
with 3μM of Rhodamine B labeled SA-D-K6L9-AS for live confocal imaging.51 A. Green 
fluorescence for Mitotracker Green FM. B. Red fluorescence for Rhodamine-B labeled SA-D-K6L9-AS. C. Bright 
field image. D. Overlap of (A) (B) and (C). 400x magnification. Picture captured at 20min after monitoring 
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on their surface. Then a lipid layer made from three lipid components would be used to envelope 
the MSNs. This lipid layer could be disrupted and release the product when the it is hit with the 
correct non-invasive radio frequency causing temperature increase. The temperature increase is 
due to the vibration of the iron oxide nanoparticles.  
 Materials and Methods  
 Synthesis of SA-K6L9-AS Variant 
The peptide chain was modified to contain a “lego” peptide or a portion of a peptide that 
will bind to itself and make a self-assembling peptide. The lego peptide chosen was RARA-
DADA. Where the positively charged arginine side chains will interact with the negatively charged 
aspartic acid side chains. The new sequence reads RARADADA-SA-LKLLKKLLKKLLKLL-AS. 
Solid phase synthesis was used as descried in Chapter 3 – Gatekeeper Synthesis to synthesis the 
peptide. 
Figure 4.5: Diagram of the proposed method for synthesizing radio frequency responsive 
MSNs and their triggered release. 
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 MSN Synthesis  
Synthesizing the MSNs directly around the peptide proved to be more challenging than 
anticipated. The original procedure using NH4OH at the catalyst was problematic because the 
peptide precipitated out of solution in basic conditions. For this reason, new methods were 
explored. 
 Ammonium Hydroxide Catalyzed 
In this method approximately 100mg of peptide was dissolved in 70ml of diH2O. Then 
9600μl of 28-30% NH4OH and 7ml ethyl acetate were added. When this occurred, the peptide 
precipitated out. The solution with peptide was allowed to sit for six days as the peptide slowly re-
dissolved. Once the solution was clear, 200μl TEOS was added with stirring at 80oC. The solution 
was stirred for 24 hours, but little precipitate formed. The solution was then allowed to sit at room 
temperature without stirring for one week at which point the white precipitate was collected via 
centrifugation (10 minutes, 10000rpm). The precipitate was washed three times with 5ml diH2O 
and three times with 5ml ethanol before being lyophilized.  
 Tween Entrapment with Sodium Fluoride Catalyst 
The tween encapsulation technique followed a modified version of a previously reported 
procedure.52 The method uses Tween 80 which is a non-toxic, nonionic surfactant and emulsifier 
that is commonly used in foods and cosmetics, to entrap the peptide within its micelle before the 
silica scaffold is constructed.53 This was done by placing 10ml of Tween 80 aqueous solution 
(10mg/ml), 5ml of aqueous peptide (2mg/ml), and 1.5ml of 0.01M NaF in a flask and diluting to 
50ml with diH2O. This solution was stirred for 15 minutes to allow for the formation of micelles. 
Then 500μl TEOS was added dropwise. The solution was stirred for approximately 18 hours. Then 
the cloudy white precipitate was collected via centrifugation (10 minutes, 10000rpm). The 
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precipitate was washed three times with 5ml diH2O and three times with 5ml ethanol before being 
lyophilized. Then the procedure was repeated using Rhodamine B labeled peptide. 
 Control Tween MSNs 
Control MSNs were synthesized using the Tween method. This performed by placing 10ml 
of Tween 80 aqueous solution (10mg/ml) and 1.5ml of 0.01M NaF in a flask and diluting to 50ml 
with diH2O. This solution was stirred for 15 minutes to allow for the formation of micelles. Then 
500μl TEOS was added dropwise. The solution was stirred for approximately 18 hours. Then the 
cloudy white precipitate was collected via centrifugation (10 minutes, 10000rpm). The precipitate 
was washed three times with 5ml diH2O and three times with 5ml ethanol before being lyophilized. 
 Sodium Fluoride Catalyzed  
After considering the fact the peptide being used should self-assemble, the procedure was 
modified to exclude Tween 80. This was done by dissolving 25-50mg of Rhodamine B labeled 
peptide in 45ml diH2O. Then 1.5ml of 0.1M NaF was added and the solution was diluted to 50ml 
with diH2O. This solution was stirred for 15 minutes to allow for the peptide to self-assemble. 
Then 500μl TEOS was added dropwise. The solution was stirred for approximately 18 hours. Then 
the cloudy white precipitate was collected via centrifugation (10 minutes, 10000rpm). The 
precipitate was washed three times with 5ml diH2O and three times with 5ml ethanol before being 
lyophilized. This procedure was repeated using unlabeled peptide, but the yield was approximately 
half the amount. 
 Control Sodium Fluoride Catalyzed  
Control MSNs following the NaF catalyzed procedure were attempted. 1.5ml 0.1M NaF 
was diluted to 50ml with diH2O. The solution was stirred at room temperature while adding 500μl 
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of TEOS. After 24 hours no precipitate had formed. The solvent was slowly evaporated to be sure 
product would not form. After 24 hours of slow evaporation, no precipitate formed. 
 Iron Oxide Nanoparticle Coating 
Iron Oxide Nanoparticles have previously been synthesized by Dr. Hongwang Wang in the 
Bossmann Group. In this procedure, 66mg of Polyvinylpyrrolidone (PVP, molecular weight: 
10000 g/mol) was dissolved in 8.8mL of D.I. water with vigorous stirring. Then 0.2mL of FeCl3 
aqueous solution (100 mg/mL) was then added to the PVP solution, and further stirred at room 
temperature for 60 minutes. Next, 1mL of dopamine aqueous solution (10mg/mL) was added to 
the above solution. The reaction mixture was further stirred at room temperature for 24 hours, and 
then transferred to a dialysis membrane bag (molecular weight cutoff 8000) and dialyzed against 
3L of D.I. water for 24 hours. The solution that was left in the dialysis bag was transferred to a 
centrifuge tube and lyophilized to dryness overnight. 
To incorporate the iron oxide nanoparticles onto the MSNs a one-pot method was 
employed without the use of dialysis. First, 25mg of NaF catalyzed, Rhodamine B labeled-peptide 
loaded MSNs, 33mg PVP, and 10mg FeCl3 were dispersed into 17.6mL diH2O with the aid of 
sonication. The reaction mixture was stirred at room temperature for 90 minutes to ensure the even 
disperse of iron precursor into the channel of MSNs. Next, 0.5mL dopamine aqueous solution was 
added to the dispersion and stirred at room temperature for 24 hours. The MSNs entrapped with 
iron oxide nanoparticles were collected by centrifugation (10min, 10000rpm). 
 Lipid Bilayer Envelope  
The next step of the gatekeeping system implemented a lipid bilayer envelope around the 
iron oxide imbedded MSNs. This was done following a previously published procedure.54 The 
thermo-responsive lipid bilayer will be composed of DPPC/DSPC/Chol/DSPE-PEG2000 at a 
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molar ratio of 65:5:25:5. The mixture was dissolved in chloroform at 5mg/ml. After a lipid film 
was formed the chloroform was removed using rotary evaporation. Then, 25mg of the MSNs 
described above were dispersed on top of the lipid film and the lipid film was re-hydrated for 15 
minutes at 37 °C. The suspension was then sonicated to fuse the lipid bilayers and MSNs. The 
resulting MSNs were collected by centrifugation (10min, 10000rpm) and lyophilized.  
 Cell Viability Assays 
Cell viability was tested utilizing a colorimetric assay modified by the Dr. Troyer lab. First 
a stock solution of 5mg/ml methylthiazolyldiphenyl-tetrazolium bromide (MTT) in 1XPBS was 
made. The stock was aliquoted out and frozen until ready for use. The three cell lines: GL26, 
B16F10, and NSC, were plated in 96-well plates at approximately 15,000 cells/cm2. GL26 and 
B16F10 require 10% fetal bovine serum in RPMI (10% FBS RPMI). NSC cells require Neural 
Stem Cell medium (NSC medium). The plates were incubated at 37oC for 24 hours. At this time, 
the medium was removed and replaced with 100μl respective medium and varying concentrations 
of 2mg/ml reagent in 1XPBS. The final concentrations of the wells were: 0mg/ml (100μl medium, 
100μl 1XPBS), 0.01mg/ml, 0.05mg/ml, 0.10mg/ml, 0.25mg/ml, 0.50mg/ml, 0.75mg/ml, and 
100mg/ml. Each reagent had three replicas of each concentration.  
The plates were then returned to the incubator for either 24 hour and 48 hours. At the given 
time, the plates were removed and the medium and reagent were suctioned off. All wells were 
rinsed once with 100μl of 1XPBS to remove settled MSNs. Then 10μl MTT stock per 100μl 
medium was added back into all wells (110μl per well) and incubated for 4 hours. Then 100μl of 
10% SDS in 0.01M HCl was added to all wells and incubated overnight. 
The absorbance was read at 550nm and 690nm using UV/Vis plate reader (Synergy H1 
micro-plate reader BioTek, Winooski, VT) and analysis software Gen5 v2.05 (BioTek Winooski, 
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VT). The difference (A690-A550) was used to create the cell viability assays. Sample calculations 
can be found in Appendix B – Sample Cell Viability Assay Calculations.  
 
 Results and Characterization 
All synthesized MSNs were characterized using Dynamic Light Scattering (DLS), Zeta 
potential, thermogravimetric analysis (TGA), and transmission electron microscopy (TEM) with 
the assistance of Joe Hammer and Sonia Barrett. DLS, Zeta Potential, and TGA were run in the 
same manner described in Chapter 3 – Materials and Methods. TEMs were run in the Electron 
Microscopy Lab out of Kansas University with the assistance of Dr. Prem Thapa.  
1 2 3 4 5 6 7 8 9 10 11 12
SPL1:1 SPL1:1 SPL1:1 SPL2:1 SPL2:1 SPL2:1 SPL3:1 SPL3:1 SPL3:1 SPL4:1 SPL4:1 SPL4:1 Well ID
0 0 0 0 0 0 0 0 0 0 0 0 Conc/Dil
SPL1:2 SPL1:2 SPL1:2 SPL2:2 SPL2:2 SPL2:2 SPL3:2 SPL3:2 SPL3:2 SPL4:2 SPL4:2 SPL4:2 Well ID
0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 Conc/Dil
SPL1:3 SPL1:3 SPL1:3 SPL2:3 SPL2:3 SPL2:3 SPL3:3 SPL3:3 SPL3:3 SPL4:3 SPL4:3 SPL4:3 Well ID
0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 Conc/Dil
SPL1:4 SPL1:4 SPL1:4 SPL2:4 SPL2:4 SPL2:4 SPL3:4 SPL3:4 SPL3:4 SPL4:4 SPL4:4 SPL4:4 Well ID
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Conc/Dil
SPL1:5 SPL1:5 SPL1:5 SPL2:5 SPL2:5 SPL2:5 SPL3:5 SPL3:5 SPL3:5 SPL4:5 SPL4:5 SPL4:5 Well ID
0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 Conc/Dil
SPL1:6 SPL1:6 SPL1:6 SPL2:6 SPL2:6 SPL2:6 SPL3:6 SPL3:6 SPL3:6 SPL4:6 SPL4:6 SPL4:6 Well ID
0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Conc/Dil
SPL1:7 SPL1:7 SPL1:7 SPL2:7 SPL2:7 SPL2:7 SPL3:7 SPL3:7 SPL3:7 SPL4:7 SPL4:7 SPL4:7 Well ID
0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 Conc/Dil
SPL1:8 SPL1:8 SPL1:8 SPL2:8 SPL2:8 SPL2:8 SPL3:8 SPL3:8 SPL3:8 SPL4:8 SPL4:8 SPL4:8 Well ID
1 1 1 1 1 1 1 1 1 1 1 1 Conc/Dil
1 2 3 4 5 6 7 8 9 10 11 12
1.145 1.103 1.152 1.166 1.109 1.144 1.149 1.174 1.234 1.213 1.257 0.924 550
0.045 0.045 0.046 0.046 0.047 0.049 0.049 0.048 0.05 0.05 0.052 0.047 690
1.1 1.058 1.106 1.12 1.062 1.095 1.1 1.126 1.184 1.162 1.205 0.877 Delta
0.831 0.676 0.757 0.887 0.842 0.99 1.299 1.061 1.082 1.025 1.006 0.821 550
0.051 0.051 0.05 0.05 0.048 0.05 0.052 0.051 0.05 0.05 0.05 0.048 690
0.78 0.625 0.707 0.837 0.794 0.94 1.247 1.01 1.033 0.975 0.955 0.773 Delta
0.805 0.72 0.686 0.606 0.624 0.749 1.138 0.95 0.861 0.916 0.878 0.662 550
0.052 0.051 0.053 0.052 0.053 0.054 0.058 0.057 0.056 0.057 0.059 0.057 690
0.753 0.669 0.633 0.554 0.572 0.695 1.08 0.893 0.805 0.86 0.82 0.605 Delta
0.26 0.169 0.228 1.051 1.091 1.13 0.863 0.873 0.94 0.999 0.985 0.726 550
0.058 0.057 0.057 0.064 0.064 0.064 0.061 0.061 0.062 0.061 0.06 0.058 690
0.202 0.112 0.171 0.987 1.027 1.066 0.802 0.812 0.878 0.938 0.924 0.667 Delta
0.186 0.12 0.108 0.146 0.109 0.11 0.877 0.755 0.811 0.894 0.826 0.803 550
0.057 0.057 0.058 0.061 0.061 0.062 0.07 0.07 0.078 0.072 0.072 0.072 690
0.129 0.063 0.05 0.085 0.048 0.048 0.807 0.685 0.733 0.822 0.754 0.731 Delta
0.148 0.116 0.113 0.113 0.112 0.112 0.838 0.874 0.787 1.024 0.975 0.863 550
0.069 0.069 0.068 0.069 0.069 0.069 0.081 0.08 0.081 0.078 0.077 0.075 690
0.079 0.048 0.045 0.044 0.043 0.043 0.757 0.794 0.706 0.947 0.897 0.788 Delta
0.108 0.12 0.118 0.118 0.12 0.119 1.027 0.944 0.915 1.175 1.148 0.942 550
0.07 0.07 0.071 0.073 0.074 0.075 0.097 0.095 0.106 0.093 0.095 0.09 690
0.038 0.049 0.047 0.045 0.046 0.044 0.93 0.849 0.809 1.082 1.053 0.852 Delta
0.124 0.129 0.128 0.132 0.128 0.128 0.862 0.866 0.906 1.147 1.124 1.065 550
0.081 0.082 0.082 0.083 0.083 0.082 0.119 0.111 0.129 0.096 0.099 0.096 690
0.043 0.047 0.046 0.049 0.046 0.045 0.744 0.756 0.777 1.051 1.025 0.969 Delta

















Figure 4.7: Sample Layout of 96-well Plates for Cell Viability Assays. 
Figure 4.6: Sample Results for Cell Viability Assays. 
1 2 3 4 5 6 7 8 9 10 11 12
: : : : : 4:1 L4:1 L4:1 Well ID
0 0 Conc/Dil
SPL1:2 SPL1:2 SPL1:2 SPL2:2 SPL2:2 SPL2:2 SPL3:2 SPL3:2 SPL3:2 SPL4:2 SPL4:2 SPL4:2 Well ID
0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 Conc/Dil
SPL1:3 SPL1:3 SPL1:3 SPL2:3 SPL2:3 SPL2:3 SPL3:3 SPL3:3 SPL3:3 SPL4:3 SPL4:3 SPL4:3 Well ID
0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 Conc/Dil
SPL1:4 SPL1:4 SPL1:4 SPL2:4 SPL2:4 SPL2:4 SPL3:4 SPL3:4 SPL3:4 SPL4:4 SPL4:4 SPL4:4 Well ID
0. 0. 0. 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Conc/Dil
SPL1:5 SPL1:5 SPL1:5 SPL2:5 SPL2:5 SPL2:5 SPL3:5 SPL3:5 SPL3:5 SPL4:5 SPL4:5 SPL4:5 Well I
0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 Conc/Dil
SPL1:6 SPL1:6 SPL1:6 SPL2:6 SPL2:6 SPL2:6 SPL3:6 SPL3:6 SPL3:6 SPL4:6 SPL4:6 SPL4:6 Well ID
0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Conc/Dil
SPL1:7 SPL1:7 SPL1:7 SPL2:7 SPL2:7 SPL2:7 SPL3:7 SPL3:7 SPL3:7 SPL4:7 SPL4:7 SPL4:7 Well ID
0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 Conc/Dil
SPL1:8 SPL1:8 SPL1:8 SPL2:8 SPL2:8 SPL2:8 SPL3:8 SPL3:8 SPL3:8 SPL4:8 SPL4:8 SPL4:8 Well ID
1 1 1 1 1 1 1 1 1 1 1 1 Conc/Dil
1 2 3 4 5 6 7 8 9 10 11 12
1 145 1 103 1 1 2 1 166 1.109 1.144 .14 .174 .234 .213 1.257 0.924 550
. 45 . 45 0.046 0.046 . 7 0.049 . 49 . 48 . .05 . 2 0.047 690
1.1 1.058 1.106 1.12 1.062 1.095 1.1 1.126 1.184 1.162 1.205 0.877 Delta
0.831 0.676 0.757 0.887 0.842 0.99 1.299 1.061 1.082 1.025 1.006 0.821 550
0.051 0.051 0.05 0.05 0.048 0.05 0.052 0.051 0.05 0.05 0.05 0.048 690
0.78 0.625 0.707 0.837 0.794 0.94 1.247 1.01 1.033 0.975 0.955 0.773 Delta
0.805 0.72 0.686 0.606 0.624 0.749 1.138 0.95 0.861 0.916 0.878 0.662 550
.05 .051 .053 .052 0. 53 0. 54 .058 .057 .056 .057 0.059 0.057 690
753 0.669 633 554 .572 0.695 1.08 .893 . 05 0.86 0.82 0.605 Delta
0.26 0.169 0.228 1.051 1.091 1.13 0.863 0.873 0.94 0.999 0.985 0.726 550
0.058 0.057 0.057 0.064 0.064 0.064 0.061 0.061 0.062 0.061 0.06 0.058 690
0.202 0.112 0.171 0.987 1.027 1.066 0.802 0.812 0.878 0.938 0.924 0.667 Delta
0.186 0.12 0.108 0.146 0.109 0.11 0.877 0.755 0.811 0.894 0.826 0.803 550
0.057 0.057 0.058 0.061 0.061 0.062 0.07 0.07 0.078 0.072 0.072 0.072 690
0.129 0.063 0.05 . 85 . 48 . 48 .80 .68 .733 .822 0.754 .731 Delta
14 116 113 113 .112 .112 .8 8 . 74 .787 . 24 0.975 0.863 550
.069 .06 .06 .069 .069 .069 .081 0.08 .081 0.078 0.077 0.075 690
0.079 0.048 0.045 0.044 0.043 0.043 0.757 0.794 0.706 0.947 0.897 0.788 Delta
0.108 0.12 0.118 0.118 0.12 0.119 1.027 0.944 0.915 1.175 1.148 0.942 550
0.07 0.07 0.071 0.073 0.074 0.075 0.097 0.095 0.106 0.093 0.095 0.09 690
0.038 0.049 0.047 0.045 0.046 0.044 0.93 0.849 0.809 1.082 1.053 0.852 Delta
0.124 0.129 0.128 0.132 0.128 0.128 0.862 0.866 0.906 1.147 1.124 1.065 550
0.081 0.082 0.082 0.083 0.083 0.082 0.119 0.111 0.129 0.096 0.099 0.096 690
0.043 0.047 0.046 0.049 0.046 0.045 0.744 0.756 0.777 1.051 1.025 0.969 Delta

















 Peptide Loaded MSNs 
Peptide loaded MSNs (P-MSNs) and Rhodamine B labeled-peptide loaded MSNs (R-
MSNs) were synthesized with and without Tween 80. For sake of clarity those synthesized with 
Tween 80 will be referred to as Tween P-MSNs or Tween R-MSNs.  
 DLS 
DLS was used as a starting point in determining the effective diameters of each MSN. 
 P-MSNs 
P-MSNs had an average effective diameter of nearly 2000nm. There were two distinct 
populations. One was 3330nm and the other was around 300nm. This suggested that there was 
aggregation in the sample. Potentially, the MSNs could be clustering in groups of three or more 
from these results. DLS results can be observed in Figure 4.8. 
Figure 4.8: DLS of P-MSNs. 
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 R-MSNs 
The DLS for R-MSNs showed to 
major populations as seen in Figure 4.9. 
The major population was large at 
approximately 3200nm. The smaller 
population was around 200nm. It was 
assumed that the major population was 
due to aggregation.  
 
Figure 4.9: DLS of R-MSNs. 
 Tween P-MSNs 
The DLS of Tween P-MSNs showed two major populations. The first population was 
approximately 450nm and the second was nearly 3200nm. Again, this suggests that the MSNs 
were aggregating greatly. The MSNs were also assumed to be larger than anticipated given that 
the smaller population measured close to half a micron.   
Figure 4.10: DLS of Tween P-MSNs. 
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 Tween R-MSNs 
The Tween R-MSNs also showed to 
populations (Figure 4.11). The smaller population 
was still large at about 1600nm. This was the most 




Figure 4.11: DLS of Tween R-MSN. 
 Zeta Potential 
Zeta potential was measured to determine the surface charge of the MSNs. This 
information is important for resulting aggregation and cell studies. 
 P-MSNs 
The Zeta potential for P-MSNs was barely positive at approximately 3mV. This is very 
close to neutral and would explain the DLS results that had large population sizes. 
Figure 4.12: Zeta Potential for P-MSNs. 
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 R-MSNs 
There Zeta potential was extremely close to neutral which would like lead to aggregation. 
Figure 4.13: Zeta Potential of R-MSNs. 
 Tween P-MSNs 
The Zeta potential for Tween P-MSNs was again found to be less neutral at approximately 
-18mV. This was not as neutral as expected considering that the DLS showed what was assumed 
to be aggregation. It is possible aggregation still occurs. 
Figure 4.14: Zeta Potential of Tween P-MSNs. 
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 Tween R-MSNs 
There Zeta potential for Tween R-MSNs was more negative around -20mV. This did not 
completely explain the large DLS diameter readings. TEM images were necessary to determine 
the true size and morphology of the structures. 
Figure 4.15: Zeta Potential of Tween R-MSNs. 
 TGA 
TGA was ran to determine the loading efficiency of each MSN. 
 P-MSNs 
Looking at the TGA data in Figure 4.16 and Figure 4.17, the weight lost from 100-500oC 
was due to loaded material and likely from the peptide (given the same temperature range). The 
loading efficiency was determined to be about 3.5% (w/w). A summary of the data used can be 
found in Table 4.1 This is still a success considering the loading efficiency of peptide into MSN 
post-synthesis was only around 1%.   
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Table 4.1: Summation of TGA Data Calculations. 
Figure 4.17: TGA of P-MSN and Peptide. 
 Peptide Control P-MSN 






Exact Temp, Wt % 100.0157 96.95543 100.0199 98.33155 100.0206 96.96505 
Exact Temp, Wt % 500.0384 24.95283 500.0352 96.50185 500.0641 91.60806 








Figure 4.16: TGA of Acid Washed P-MSNs. 
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 R-MSNs 
The TGA results of R-MSNs indicated about 3% loading efficiency. This is close to the P-
MSNs. Given the yield was much higher than that of the P-MSNs, it can be assumed that having 
the hydrophilic rhodamine B attached to the end of the peptide helped form better micelles to build 
around resulting in a higher yield of MSNs. 
Figure 4.18: TGA of R-MSN and Rh. B-labeled Peptide.  
 
 Control Tween MSNs 
Control Tween MSNs were run to determine the amount of Tween 80 typically entrapped 
in the MSNs without the addition of peptide. The calculations showed the weight lost from 100-
500oC was 37% and the total weight lost from the MSN from 100-700oC was about 42%. The 
shape of the TGA curve can also be used to help determine if peptide was successfully loaded. If 
the shape of the curve differs then Tween 80 was not added alone. Looking at the comparison of 
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the three TGA curves below, it is clear that both the Tween P-MSN and Tween R-MSNs differ in 
pattern. 
Figure 4.19: TGA Comparison of Control, Tween P-MSNs, and Tween R-MSNs. 
 Tween P-MSNs 
The TGA for Tween MSNs showed a 36.5% loading efficiency. This was not completely 
peptide, as some of this was Tween 80. Considering the ratio of peptide to tween during synthesis  
Figure 4.20: TGA of Tween P-MSN. 
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was 1:10, the true peptide loading was likely closer to 3.6%. This is approximately the same as the 
P-MSN loading efficiency. The loading efficiency being slightly lower than that of the control 
suggested that when the non-labeled peptide self-assembles and/or is trapped in the Tween 80 
micelle, solvent is also incorporated. This is evident from the much larger solvent loss from 0-
100oC. 
 Tween R-MSNs 
The Tween R-MSNs exhibited a similar TGA to that of the Tween P-MSNs. This suggested 
a similar morphology and loading efficiency. The loading efficiency was calculated to be to be 
approximately 36.2% from 100-500oC. The assumption can be made that one tenth of this loading 
is peptide resulting in approximately 3.6% loading of Rhodamine-B labeled peptide. It is notable 
that the weight drop occurred at a later temperature than that of the control. There is also a distinct 
difference in weight loss from temperatures 100-300oC of approximately 3% further suggesting a 
loading efficiency of around 3% peptide. It is also notable that the was not a large solvent lost prior 
to 100oC as was seen in the Tween P-MSNs. This suggested the incorporation of Rhodamine-B to 
the peptide either changed the way that it self-assembles or the way it is entrapped by Tween 80. 




P-MSNs had two different morphologies in their sample. The major structure was meso-
mesh made up of multiple small nanoparticles. The less common product was nanostructures 
shown in Figure 4.16. Both structures are highly porous as show in Figure 4.17. Aggregation was 
also evident in the TEM images, confirming the assumption made from DLS and Zeta potential.  
Figure 4.22: TEM of the Two Structures Found in P-MSNs. 




Unfortunately, the TEM images were not able to be taken for R-MSNs. It was expected 
that their structure would be similar to that of the P-MSNs, but due to the differences in earlier 
characterization this cannot be a definitive. There were also differences observed for the TEMs of 
Tween MSNs with and without Rhodamine B, making it even more plausible that the structure 
may be slightly different. 
 Control Tween MSNs 
Control Tween MSNs TEMs did not show a uniform structure. This was surprising, as the 
expected result was nearly sphere-like structures which were observed when the protocol was used 
to entrap DOX.52 The porous, disordered structures can be seen below.  
Figure 4.24: TEM of Control Tween MSNs. 
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 Tween P-MSNs 
The Tween P-MSNs had a completely different morphology than the P-MSNs and slightly 
different even from the control Tween MSNs. The images indicate that small nanostructures are 
clustering together to form larger nanostructures, but there is no longer “meso-mesh”. The 
structures are highly porous. These structures may be easier to envelope in lipid. The average size 
of the larger nanostructures was just under 900nm.  
Figure 4.25: TEM of Tween P-MSNs Secondary Structures. 
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Figure 4.26: Closer View of Tween P-MSN TEM to Show Porosity. 
 Tween R-MSNs 
Tween R-MSNs had an interesting structural change in comparison to Tween P-MSNs. 
The Tween R-MSNs were spherical in structure and varied greatly in size. The largest spheres 
were well over 500nm, but the 
smallest where near 20-30nm. The 
structures were highly porous which 
can be observed from the zoomed 
TEM images. Overall, the Rhodamine 
B attachment clearly affects the 
structural outcome of the MSNs. With 
modification of the procedure it is 
hoped that the size of the resulting 
MSNs can be better controlled to 
provide more uniformity. 
Figure 4.27: TEM of Tween R-MSNs. 
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Figure 4.28: TEM of Tween R-MSNs to Show Porosity. 
 
 Iron Oxide Nanoparticle Imbedded, Peptide Loaded MSNs 
 DLS 
R-MSNs imbedded with iron oxide 
nanoparticles (JH-MSNs) were first characterized 
using DLS. As with the other NaF catalyzed 
structures, there seemed to be much aggregation. 
The estimated diameter was 3353nm. The true size 
of the MSNs would need to be determined by TEM, 
but clustering was taking place in solution.  
Figure 4.29: DLS of JH-MSNs. 
 Zeta Potential 
The zeta potential of JH-MSNs was closer to zero at only -13mV. The peak was also not 
uniform suggesting that some populations within the sample may have a slightly higher or lower 
surface charge. Either way the closeness to neutral explains the aggregation. The zeta potential 
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also closely resembled that of published work, suggesting the successful incorporation of iron 
oxide nanoparticles.55 
 
Figure 4.30: Zeta Potential of JH-MSNs. 
 TGA 
The TGA of the JH-MSNs showed a much more rapid release of the encapsulated peptide. 
This was assumed to be due to the polymer coating. Once it breaks down the peptide is released. 
The loading efficiency was estimated to high at be 16%, considering R-MSN’s was only 3%. 
Figure 4.31: TGA of R-MSN vs. JH-MSN. 
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 TEM 
Along with TEM, Energy-Dispersive X-ray spectroscopy (EDX) was also used to analyze 
JH-MSNs. EDX can measure the elemental content of the structures analyzed by TEM. This was 
used to confirm the presence of iron in the sample. Looking at the images in Figure #, polymer 
coats the mesoporous structures and iron oxide NPs are imbedded within the polymer. The 
structures are still porous, which can be observed in Figure #, but have decreased slightly in their 
porosity. In Figure #, the element content was mapped for carbon, nitrogen, oxygen, silica, and 
both iron-K and iron-L. The presence of all of the elements proved the nanostructures consisted of 
the desired reagents.  
Figure 4.32: TEM of JH-MSNs. 
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Figure 4.33: STEM of JH-MSN Structures. 
Figure 4.34: EDX Element Mapping of JH-MSNs. Elements Depicted: Carbon (red), 
Nitrogen (orange), Oxygen (blue), Silica (green), Iron-K and Iron-L Respectively (yellow). 
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 Lipid Enveloped MSNs 
From here on the lipid enveloped, iron oxide nanoparticle imbedded, Rhodamine B 
labeled-peptide loaded MSNs will be referred as JLH-MSNs 
 DLS 
The DLS for the lipid enveloped JH-
MSNs was smaller than JH-MSNs alone. It also 
showed two populations. This was believed to 
be due to the lipid limiting aggregation slightly. 
The populations were still far larger than 
anticipated.  
 
Figure 4.35: DLS of JLH-MSNs. 
 Zeta Potential 
The Zeta potential after lipid enveloping was slightly closer to neutral, but still negative 
as seen in Figure 4.36. It was expected to increase more due to the positive charge on the lipids.  
Figure 4.36: Zeta Potential of JHL-MSNs. 
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 TGA 
The TGA results gave the most indication of lipid enveloping. The loading efficiency was 
calculated to be 28% for the appropriate temperature range. This was a 12% increase from JH-




The TEM images showed that the lipid nicely covered the porous meso-mesh. This was an 
exciting result and confirmed the findings of the TGA experiments previously performed. It was 
expected that the coverage would keep the peptide inside the structure and decrease toxicity of the 
MSNs.  
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Figure 4.37: TEM of JLH-MSNs.  
 Cell Viability Assays 
Percent cell viabilities were calculated and plotted against concentration of reagent using 
GraphPad Prism. The data plotted was the mean and error (standard deviation) of 3 side by side 
replicas. A chart showing the R2 values for each reagent at 24h and 48h for each cell line can be 
found in Appendix B. 
 MSNs Without Gatekeeping System 
 The first MSNs tested were P-MSNs, R-MSNs, Tween P-MSNs, and Tween R-MSNs. 
The all MSNs tested exhibited activity toward both cancer cell lines and slightly less activity 
toward the NSC cell line.  
 NSC Cell Line 
For the NSC cell line it was hoped that there would be less cell death than in other cell 
lines. Unfortunately, it is known the peptide is not selective and would kill the NSCs if a 
gatekeeping system is not in place. At 24h, the R-MSNs exhibited the lowest median lethal dose 
(LC50), then Tween P-MSNs, then P-MSNs third, and finally Tween R-MSNs had the highest LC50 
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in comparison. This was 
encouraging because the yields for 
Tween P-MSNs are significantly 
higher than that of the P-MSNs and 
less peptide would be required to 
make them with the same killing 
efficiency. This could be beneficial 
when moving to in-vivo and 
determining dosing.  It should also 
be noted that although Tween R-
MSNs had the highest LC50, it 
killed the most cells at highest 
concentrations. This is clear when 
looking at figure 4.8a. 
For the 48h trial, theLC50 trend changed slightly with P-MSNs having the lowest LC50, 
then Tween R-MSNs, then Tween P-MSNs. Unfortunately, for some reason the 48h NSC trials 
were problematic giving very large 95%CI ranges for both P-MSNs and R-MSNs making the data 
unreliable. Again, The Tween R-MSNs killed the most cells at high concentrations. Though this 
did further encourage the use of Tween based MSNs. The LC50 values with 95%CI are summarized 
in Table 4.2.  
Figure 4.38: Cell Viability Assays of Neural Stem 
Cells against MSNs Without Gatekeepers at 24h and 
48h. P-MSN (red), R-MSN (blue), Tween P-MSN (green), and 
Tween R-MSN (black). 
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Table 4.2: LC50 Values in mg/ml and 95% Confidence Intervals for MSNs without  
Gatekeepers against NSC Cell Line. 
 B16F10 Cell Line 
When tested against the B16F10 cell line all four MSNs showed increased activity in 
comparison to their activity against NSC. The 24h trial showed excellent LC50 values for all four 
MSNs summarize in TABLE #. Looking at both the 24h and 48h trials it became clear that the 
MSN with the best overall activity was Tween P-MSNs. The Tween R-MSNs had a statistical 
outlier at 0.1mg/ml concentration, so it was removed from the plotted and calculated data.    
 
Figure 4.39: Cell Viability Assays of B16F10 against MSNs Without Gatekeepers at 24h 
and 48h. P-MSN (red), R-MSN (blue), Tween P-MSN (green), and Tween R-MSN (black). 
LC50 Values P-MSN R-MSN Tween P-MSN Tween R-MSN 
24 hours 0.008419 0.004968 0.007262 0.03562 
 0.005788 to 0.01544 0.002929 to 0.01636 0.004768 to 0.01523 0.02442 to 0.06581 
48 hours 0.01299 ~ 295.1 0.05496 0.04912 
 (0.005588 to +infinity) (Very wide) 0.03173 to 0.2050 0.03614 to 0.07665 
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Table 4.3: LC50 Values in mg/ml and 95% Confidence Intervals for MSNs without 
Gatekeepers against B16F10 Cell Line. 
 GL26 Cell Line 
In the past, D-K6L9 showed the best activity toward GL26 cell lines, but after running these 
trials it was clear that the self-
assembling peptide’s activity 
toward GL26 cells and B16F10 
cells was approximately the same. 
Again, when the four MSNs were 
tested all had great activity at both 
24h and 48h. when looking at the 
LC50 values summarized in Table#, 
Tween P-MSNs have the best 
overall activity because their LC50 
is not only the lowest, but it is 
consistent. It is believed that the 
bulky structure of Rhodamine B 
may cause the peptide to get slight 
Figure 4.40: Cell Viability Assays of Neural Stem Cells 
against MSNs Without Gatekeepers at 24h and 48h. P-
MSN (red), R-MSN (blue), Tween P-MSN (green), and Tween R-
MSN (black). 
LC50 Values P-MSN R-MSN Tween P-MSN Tween R-MSN 
24 hours 0.004544 0.008459 0.005283 0.05013 
 0.003733 to 0.005806 0.007120 to 0.01042 0.003730 to 0.00905 0.03555 to 0.08499 
48 hours 0.01075 0.007586 0.006859 0.02572 
 0.007289 to 0.02047 0.005095 to 0.01484 0.005354 to 0.00954 0.01753 to 0.04821 
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stuck inside the MSNs and this could be the reason that both R-MSN and Tween R-MSN have 
slightly worse activity against all three cell lines. These findings reiterate the need for a controlled 
gatekeeping system.  
Table 4.4: LC50 Values in mg/ml and 95% Confidence Intervals for MSNs without 
Gatekeepers against GL26 Cell Line. 
 JH-MSNs Against NSC Cell Line 
Due to a shortage of material the JH-MSNs where only tested against NSC cell lines. The 
expected outcome of this test was that the MSNs may have slightly lower activity due to the 
polymer coating containing iron oxide NPs, but it would not be concerning if they still showed 
activity because this was not the 
final portion of the gatekeeping 
system. The cell viability assay 
showed decreased activity as 
expected, but even at lowered 
concentration was toxic enough 
to encourage the use of a lipid 
bilayer envelope. The LC50 of 
Figure 4.41: Cell Viability Assay of JH-MSNs against 
NSC Cell Line over a 48h Period. 
LC50 Values P-MSN R-MSN Tween P-MSN Tween R-MSN 
24 hours 0.01132 0.009037 0.007723 0.04219 
 0.008745 to 0.01604 0.005652 to 0.02253 0.005177 to 0.01520 0.03064 to 0.06773 
48 hours 0.009289 0.03639 0.007200 0.02064 
 0.007867 to 0.01134 0.02351 to 0.08056 0.003752 to 0.08853 0.01437 to 0.03659 
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JH-MSNs against NSC at 48h was 0.03706mg/ml (0.02226 to 0.1106). This is 75 times less than 
the R-MSNs alone.  
 JLH-MSNs Against Various Cell Lines 
Once the MSNs had a lipid layer added they were tested against all three cell lines. The 
outcome was not exactly as expected because the MSNs still killed approximately half the 
population at low concentrations after 48h. The decreased toxicity is a great sign, but the lack of 
complete gatekeeping is likely due to the lack of uniformity in the MSN structures. This causes 
the lipid to not cover some 
portions of the material. To 
combat this issue, the MSN 
samples will be separated 
by size using a unique 
centrifuge and the 
experiment will be repeated 
with more uniformly sized 
MSNs. 
Once the MSNs had a lipid layer added they were tested against all three cell lines. The 
outcome was not exactly as expected because the MSNs still killed approximately half the 
population at low concentrations after 48h. The decreased toxicity is a great sign, but the lack of 
complete gatekeeping is likely due to the lack of uniformity in the MSN structures. This causes 
the lipid to not cover some portions of the material. To combat this issue, the MSN samples will 
be separated by size using a unique centrifuge and the experiment will be repeated with more 
uniformly sized MSNs. Although the calculated LC50 is low, it is also notable that significantly 
Figure 4.42: Cell Viability Assay of JLH-MSNs Against 
Several Cell Lines over a 48h Period. 
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less cell death occurred at all concentrations with the addition of the gatekeeping system. Also, 
with the exception of the B16F10 cell line the R2 values of the calculated graphs are very low.  
Table 4.5: LC50 Values is mg/ml and 95% Confidence Intervals of JLH-MSNs against NSC, 
B16F10, and GL26 Cell Lines. 
 
 Discussion 
In this chapter the successful incorporation of an anti-cancer, self-assembling peptide into 
a mesoporous nanostructure was shown. The incorporation was done in a one-pot method either 
using Tween 80 as a templating agent or without Tween 80 using the peptide alone as the 
templating agent. All the peptide incorporated MSNs showed great activity against the melanoma 
and glioma cancer cell lines. Unfortunately, their toxicity was still high against NSC cell lines. 
The design and application of a novel radio-frequency release gatekeeping system was also 
discussed. This gatekeeping system limits the toxicity of the MSNs via a triggered release of the 
encapsulated peptide. The preliminary trials were promising. Iron oxide NPs were successfully 
imbedded in a polymer coating off the MSN structure and a lipid layer was successfully added to 
the MSNs. The cell viability assays showed a decrease in cell death with the applied gatekeeping 
system. Due to the lack of uniformity in the MSNs the lipid results were lackluster, but still opened 
the door for further improvement of the system.  
LC50 Values NSC B16F10 GL26 
48 hours 0.003232 0.005903 0.006800 
 0.0007237 to +infinity 0.004855 to 0.007529 0.004085 to 0.02029 
R2 0.2106 0.9722 0.7892 
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 Future Work 
The next steps for this project include finetuning the MSN synthesis protocol to achieve 
uniform structures or using a centrifuge to separate the MSNs based on size. Once this has been 
done the gatekeeper will be reapplied and the expectation is that the gatekeeping ability will be 
improved. The Tween based MSNs will also be investigated further given their LC50 values were 
the all-around best. The R-MSNs where initially used so the peptide could be more easily tracked 
in either fluorescence studies or confocal imaging. Tween R-MSN will be used in its place for 
those studies due to the spherical structure and potential ease of enveloping. Once the gatekeeper 
successfully holds the peptide in, the next rational step will be to perform release studies to 
determine if temperature increase and radio frequency will release the drug and at what rate. Then 
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Appendix A - Supplementary Data for MSNs Designed for 
Antimicrobial Use 
 Supplemental Material for Synthesized Surfactants 
 
Figure A.1: 1H-NMR of Surfactant A 
 




Figure A.3: 1H-NMR of Surfactant B-12 
 
Figure A.4: 1H-NMR of Surfactant C 
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Figure A.5: 1H-NMR of Surfactant V1 
 




Figure A.7: IR Spectrum of SB6. 
Figure A.8: IR Spectrum of SB12. 
 
Figure A.9: IR Spectrum of SC. 
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Figure A.10: IR Spectrum of V1. 
 











Figure A.12: Mass Spectroscopy Data for Vancomycin Conjugated Peptide, Full Spectra  
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Figure B.1: The Cancer-Immunity Cycle 
  “The generation of immunity to cancer is a cyclic process that can be self-propagating, 
leading to an accumulation of immune-stimulatory factors that in principle should amplify and 
broaden T cell responses. The cycle is also characterized by inhibitory factors that lead to immune 
regulatory feedback mechanisms, which can halt the development or limit the immunity. This 
cycle can be divided into seven major steps, starting with the release of antigens from the cancer 
cell and ending with the killing of cancer cells. Each step is described above, with the primary cell 
types involved and the anatomic location of the activity listed. Abbreviations are as follows: APCs, 
antigen presenting cells; CTLs, cytotoxic T lymphocytes.”48 Through necrotic cell death caused 
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by therapeutic agents, this cycle can be employed. Without a therapeutic agent to initiate the cycle, 
the body is extremely less likely to begin the cycle on its own.  
 
 Sample Cell Viability Calculation 
First the difference in absorbance (A690-A550 = delta) was determined. Then the average 
delta of the control wells containing no reagent and only medium was calculated, with the 
assumption these wells contained 100% living cells. Then the delta of every well was divided by 
this average and multiply by one hundred to give percent viability as shown below. 
𝑎𝑏𝑠. 𝑑𝑒𝑙𝑡𝑎
𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑣𝑒𝑟𝑎𝑔𝑒
∗ 100 = % 𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 
Sample example: A690-A550 = 1.100 for well A1. The average delta of control wells was 
1.0996. Cell viability for well A1 was found to be 100.04% As shown below. 
1.100
1.09958333333333
∗ 100 =  100.0378931 
